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Abstract 
Highly active antiretroviral therapy (HAART) contributes to metabolic disorders and the 
growing prevalence of metabolic syndrome (MetS) in human immunodeficiency virus 
(HIV)-infected patients. Hypertension, obesity, and hyperglycemia (components of 
MetS) are risk factors for cardiovascular disease. Studies have shown that HIV patients 
on HAART have a 2-fold risk of dying from MetS. There are no such studies in 
Umuahia; hence the need for this study to fill this gap. Using a sample size of 192 
medical records of HIV-infected patients in Federal Medical Centre, Umuahia, and 
applying metabolic syndrome theory, this study examined the relationships among types 
of HAART regimen, duration of HAART and hypertension, obesity, and hyperglycemia 
among HIV-infected adult patients. The records were stratified into 4 by duration of 
HAART. Chi-square test was used to determine associations between the nonparametric 
variables, whereas multiple logistic regressions were used to estimate the odds ratios. 
Odds of hypertension were more than 18-fold (OR = 18.52, 95% confidence interval [CI] 
= 5.464, 42.50) at >12 months on HAART, whereas odds of obesity was more than 5-fold 
(OR = 5.43, 95% CI = 2.227, 13.158) at >12 months. Odds of hyperglycemia were more 
than 14-fold at >12 months compared with <12 months on HAART. Statistical 
significance was achieved with duration of HAART for hypertension and hyperglycemia 
(p < .05) but none with types of HAART (p < .05). Being male, older age, and duration of 
HAART were associated with odds of metabolic syndrome components. This knowledge 
provides a base for population-based intervention programs for the HIV-positive 
population undergoing antiretroviral therapy in the Umuahia metropolis.          
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Chapter 1: Introduction 
Access to highly active antiretroviral therapy (HAART) significantly reduced the 
rate of human immunodeficiency virus (HIV) infection-related mortality and morbidity 
(Berhane, Yami, Alemseged, Yemane, Hamza, Kassim, & Deribe, 2012). The advent of 
HAART in the management of HIV-positive patients in 1996 brought about a significant 
reduction in the annual mortality rates in the HIV-positive population from more than 
29% to less than 2% in a space of 10 years (May, Sterne, & Costagliola, 2006). However, 
new concerns have arisen regarding the adverse effects of HAART on the metabolic 
system of HIV-infected patients (Muhammad, Sani, & Okeahialam, 2013). According to 
Muhammad et al., observed metabolic abnormalities such as hyperlipidemia, insulin 
resistance, high blood pressure, and fat redistribution constitute major risk factors for 
cardiovascular disease (CVD). These abnormalities are said to be components of the 
metabolic syndrome (MetS). However, variation exists in the risk factors by population 
characteristics and racial differences (Grundy, Cleeman, Daniels, Donato, Eckel, et al., 
2005; Ngatchoua, Lemogouma, Ndobob, Yiagnignib, Tiogoub, et al., 2013).  
I examined the relationship among HAART regimen and hypertension, obesity, 
and diabetes as metabolic syndrome components, and I examined the association among 
duration of HAART regimen and hypertension, obesity, and diabetes as metabolic 
syndrome components. The incidence of metabolic syndrome and CVD in the HIV-
positive population can be reduced and prevented through informed population–based 
intervention programs if the right attention is drawn to these modifiable risk factors. 
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In this chapter, I introduce the study topic and the overview of the study. In the 
first section of this chapter, I summarize relevant, recent literature relating HAART with 
hypertension, obesity, and diabetes as metabolic syndrome components. I also provide 
insights into the problem addressed in this study, the purpose of the study, research 
questions, and the hypotheses. In the second section, I introduce the theoretical concepts 
that formed the framework of the study; I summarize metabolic syndrome theory; and I 
describe the nature of research, definitions, scope of the study, delimitations, and 
limitations. I also highlight the significance of this study for the advancement of public 
health through positive social change.  
Background 
HIV is a lentivirus of the retrovirus family. The acquired immunodeficiency 
syndrome (AIDS) virus infects the individual through various routes of transmission and 
then invades the host’s immune system (Agyemang-Yeboah & Nkum, 2012). The 
infected person’s immune system is thus compromised, thereby creating room for life-
threatening opportunistic infections (Agyemang-Yeboah & Nkum, 2012). According to 
Agyemang-Yeboah & Nkum, the virus has the potential of surviving in body fluids and 
be transmitted from person to person.  
Using anti-HIV drugs in the treatment of individuals infected with HIV is termed 
antiretroviral therapy (World Health Organization [WHO], 2014). The therapy is a 
cocktail of at least three drugs that reduces or suppresses the replication of the HIV. The 
combined therapy is popularly called HAART (WHO, 2014). A combination of three 
drugs is used to reduce the possibility of the virus developing resistance to the drugs 
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(WHO, 2014). Using cocktail of medicines confers the unique quality that can stop the 
HIV disease progression (WHO, 2014). The drug combination reduces the rates of 
disease progression and mortality in this population of patients, thereby improving the 
quality of life of these patients (WHO, 2014). Using HAART in HIV infection 
management has led to increased prevalence of diabetes mellitus, insulin resistance, 
lipoatropy, fat redistribution, dyslipidemia, hypertension, hepatic steatosis (Currier, 
2014), and arterial stiffness (Ngatchou et al., 2013). These metabolic syndrome 
components in conjunction with other factors according to Stein and Hsue (2012) 
increase the risk for CVD.  
According to Zhou, Wang, and Yu (2014), common pathways exist between CVD 
and metabolic syndrome that are shared by patients with metabolic syndrome. These 
pathways include defective glucose metabolism, increased oxidative stress, 
hypercoagulability, and endothelial damage. In addition, hypertension and insulin 
resistance are components of metabolic syndrome that most times coexist (Zhou, 
Schulman, & Zeng, 2012). Furthermore, insulin also induces vasorelaxation through 
stimulation of nitric oxide in the endothelium in addition to its metabolic effects (Zhou et 
al., 2012). Similarly, Schulman and Zhou (2009) demonstrated that insulin resistance 
contributed to the development of CVD and hypertension in cardiovascular tissues.  
Several studies in the United States, Europe, and Canada investigated the 
incidences of CVD. The studies compared CVD in HIV-infected patients and persons 
without HIV infection (Chow, Regan, Feske, Meigs, Grinspoon et al., 2012) and CVD in 
HIV-infected patients on HAART and HIV-infected patients not on HAART (Durand, 
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Sheehy, Baril, Lelorier, & Tremblay, 2011; Freiberg, Chang, Kuller, Skanderson, Lowy 
et al., 2013; Lang, Mary-Krause, Cotte, Gilquin, Partisani et al., 2010). Their findings 
confirmed increased rates of cardiovascular events in HIV-infected patients who took 
HAART. In a similar study, the risk of heart attack and stroke was two to four times 
increased by hyperglycemia—a component of metabolic syndrome (Alberti, Eckel, 
Grundy, Zimmet, Cleeman et al., 2009). The management of chronic diseases such as 
diabetes mellitus, hypertension, and CVD in HIV-positive patients adversely affects the 
quality of life and increase the financial burden on the patient as well as the health care 
system (Centers for Disease Control and Prevention [CDC], 2013).  
HAART and Metabolic Syndrome Prevalence 
Due to the adverse metabolic effects such as increased blood pressure, 
dyslipidemia, and insulin resistance associated with HAART regimen, there have been 
reported cases of increased incidences of cardiovascular disorders in this group of the 
population (Guaraldi, Stentarelli, Zona, Orlando, Carli et al., 2010; Palios, Kadoglou, & 
Lampropoulos, 2012). Guaraldi et al. reported a 26% increase in risk for myocardial 
infarction in their study. Other reported adverse effects of HAART include arterial wall 
stiffness (Ngatchou et al., 2013) and coronary artery calcium (CAC) (Guaraldi et al., 
2010). The reported adverse effects of HAART play a role in the development of 
atherosclerosis and increased risk for myocardial infarction (Guaraldi et al., 2010; 
Ngatchou et al., 2013). The growing concern for increasing prevalence of metabolic 
abnormalities and risk of CVD among HIV-positive patients on HAART has necessitated 
several observatory cohort studies (Durand, Sheehy, Baril, Lelorier, & Tremblay, 2011; 
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Guaraldi et al., 2010; Muhammad et al., 2013; Ngatchou et al., 2013; Omech, Sempa, 
Castelnuovo, Opio, Otim et al., 2012) to determine the prevalence of metabolic 
syndrome. The studies also established the relationship between HAART and metabolic 
syndrome components, and the incidence of CVD among the HIV-positive population. 
These studies on the prevalence of metabolic abnormalities and risk of CVD among the 
HIV-positive population validate reports that metabolic syndrome prevalence varies by 
population, race/ethnicity, and age (Muhammad et al., 2013; Ngatchou et al., 2013). 
Although the prevalence of metabolic syndrome may vary by race/ethnicity and increase 
with age, the studies showed that other modifiable risk factors vary within and between 
populations (Razzouk & Muntner, 2009).  
In the United States, data from the National Health and Nutrition Examination 
Survey (NHANES) was used to monitor and estimate the U.S. population (Beltrán-
Sánchez, Harhay, Harhay, & McElligott, 2013). Increased concern regarding the 
prevalence of metabolic syndrome has prompted the CDC to conduct series of cross-
sectional studies every 2 years to assess prevalence rate of metabolic syndrome in the 
U.S. population (Beltrán-Sánchez, Harhay, Harhay, & McElligott, 2013). However, in 
Nigeria there are no such continuous studies that assess the prevalence rate of metabolic 
syndrome.  
In the NHANES studies, during physical examinations, blood samples were 
collected and analyzed to determine the presence of metabolic syndrome components 
using the harmonized definition of metabolic syndrome that defined metabolic syndrome 
as the presence of three or more of the metabolic syndrome components (Alberti et al., 
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2009). The results showed an estimate of 25% metabolic syndrome prevalence rate 
(Mozumdar & Liguori, 2011). A similar study conducted among a British cohort of 
middle-aged men estimated the prevalence of metabolic syndrome to be 26% 
(Wannamethee, 2008). The studies of Mozumdar and Liguori; Wannamethee have 
contributed in validating the reports that prevalence of metabolic syndrome varies 
between and within populations. Razzouk and Muntner (2009); Rosolova and 
Nussbaumerova (2011) also showed that there are different rates of disease progression 
and that metabolic syndrome is a marker for metabolic abnormalities. Furthermore, the 
studies by various researchers showed that there are arrays of designs and methods used 
to determine the prevalence and presence of metabolic syndrome in various populations 
(Alberti, Eckel, Grundy, Zimmet, Cleeman et al., 2009; Mozumdar & Liguori, 2011; 
Muhammad et al., 2013; Ngatchou et al., 2013; Wannamethee, 2008).  
The growing increase in the prevalence of metabolic syndrome and its 
components has been attributed to physical inactivity, unbalanced food intake, and the 
use of HAART in the HIV-positive population (Paula, Falcão, & Pacheco, 2013). Thus, 
this study focused on a group of certain metabolic factors associated with risk for 
cardiovascular disease. These metabolic factors include high blood pressure, obesity, and 
elevated blood glucose levels, (Alberti et al., 2009). Thus, the presence of any three or 
more of the five factors (elevated blood glucose levels, abnormal blood lipid levels, 
elevated triglyceride, high blood pressure, and obesity) is termed metabolic syndrome 
(Alberti et al., 2009). Grundy et al. (2005) defined metabolic syndrome as the presence of 
at least three of the five of metabolic syndrome components: (a) elevated triglycerides 
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≥150; (b) low high-density lipoprotein cholesterol <40 for men <50 for women; (c) 
elevated blood pressure of ≥130/≥85 mm Hg; (d) fasting blood glucose >100 mg/dL; (e) 
body mass index (BMI) of ≥30 kg/m2. However, only elevated blood pressure, elevated 
blood glucose, and obesity as metabolic syndrome components were employed in the 
study. Based on the guidelines of the National Cholesterol Education Program’s (NCEP) 
Adult Treatment Panel (ATP) III, the following criteria were adopted in this study: (a) 
elevated blood pressure of ≥130/≥85 mm Hg or treatment for hypertensive; (b) fasting 
blood glucose >100 mg/dL, or antidiabetic treatment; (c) BMI ≥30 kg/m2 (Anon, 1998; 
WHO, 2015). 
The observations by the NCEP and other researchers (Guaraldi et al., 2010; 
Ngatchou et al., 2013) reported that metabolic syndrome is a multiple component risk 
factor for cardiovascular disease and it is, therefore, deserving of more attention, 
especially as it concerns diet and lifestyle in the HIV-positive population.  
Problem Statement 
The introduction of HAART in the management of HIV infection has 
significantly reduced morbidity and mortality rates in HIV-positive patients (Berhane et 
al., 2012). However, HAART has created a new burden of metabolic disorders that are 
risk factors for CVD in these categories of patients (Kiage, Heimburger, Nyirenda, 
Wellons, Shashwatee et al., 2013).  
Metabolic syndrome is a major public-health and medical challenge that is on the 
increase globally (Alberti & Zimmet, 2005). In Africa, diabetes a component of MetS 
affects more than 14 million people, and it is expected that by 2030, 28 million 
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individuals will be affected (International Diabetes Federation [IDF], 2011). In Nigeria, 
reports showed that MetSprevalence rate among diabetic patients is more than 80% 
(Okafor, 2012). According to Alberti and Zimmet, metabolic syndrome patients have 
increased risk of myocardial infarction up to three- to 4-fold, of stroke up to two- to 4-
fold, and a 2-fold risk of dying from these metabolic syndrome components. 
HAART has been linked to the development of metabolic syndromes 
(Muhammad et al., 2013). According to Friis-Moller, Sabin, & Weber (2007) and 
Muhammad et al., metabolic syndrome components increases the risk of cardiovascular 
disease, heart attack, and stroke. Other known risk factors for metabolic syndromes 
include protease inhibitors (PIs); nucleosides reverse transcriptase inhibitor(s) (Wu et al., 
2012); cigarette smoking; the effect of chronic inflammation related to the infection, and 
advancing age (Steinhart & Emons, 2004). PIs target the HIV-1 PR and inhibit its 
enzymatic activity thereby preventing the cleavage of the Gag and Gag-pol that bring 
about the production of noninfectious virus particles (Adamson, 2012).  
In response to these emerging burdens of metabolic abnormalities among HIV-
positive patients treated with HAART, several researchers conducted cross-sectional 
observational studies that observed that metabolic syndrome components are prevalent in 
HIV-positive patients on HAART (Alvarez, Salazar, & Galindez., 2012; Berhane et al., 
2012; Hansen, Petersen, Haugaard, Madsbad, Obel et al., 2009; Muhammad et al., 2013; 
Omech et al., 2012;). In Nigeria, Muhammad et al. reported 21% prevalence of metabolic 
syndrome among HIV-positive patients on HAART. Wu et al. (2012) also found in their 
study conducted in Taiwan that a metabolic syndrome was developed in approximately 
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one quarter of HIV-infected patients on HAART. In Wu et al.’s study, 210 (26.2%) of 
877 HIV-positive patients developed metabolic syndrome. The results also showed an 
association among prolonged exposure to HAART, PIs; nucleoside reverse transcriptase 
inhibitor(s), and metabolic syndrome OR of 1.78 (95% confidence interval [CI], 1.03–
3.07), 1.96 (95% CI, 1.13–3.42), and 1.91 (95% CI, 1.11–3.30), respectively (Wu et al., 
2012). Hansen et al. conducted a similar cross-sectional study in the department of 
infectious diseases, Hvidovre Hospital, Denmark. The results of the study showed that 
27% of a total of 566 HIV-positive patients treated with various antiretroviral drug 
classes developed a metabolic syndrome (Hansen et al., 2009). Furthermore, Alencastro 
et al. in their cross-sectional study in southern Brazil also confirmed that metabolic 
syndrome was prevalent in southern Brazil. In the same vein, Friis-Moller et al. 
demonstrated in their data collection on adverse events of anti HIV drugs Data Collection 
on Adverse Events of Anti-HIV Drugs (DAD) study that association exists between 
antiretroviral therapies and cardiac risk factors (Friis-Moller et al., 2007). This reported 
association is partly responsible for the increase in the rate of myocardial infarction. 
Increased rate of myocardial infarction was demonstrated by an increase in relative risk 
(RR) for myocardial infarction with the use of protease inhibitor (1.16; 95% CI, 1.10–
1.23; p ≤ .001) after controlling for dyslipidemia, diabetes, and hypertension. Studies also 
showed that there is a greater risk of myocardial infarction and CVD in HIV-positive 
patients treated with HAART than are non–HIV-infected persons who are not on 
HAART (Friis-Moller et al., 2003; Triant, Lee, Hadigan, & Grinspoon, 2007; Grinspoon, 
2009). The underlying causes according to Grinspoon are multifactorial that include risk 
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factors such as the effect of chronic inflammation related to HIV infection, adverse 
metabolic effects of antiretroviral therapy, and cigarette smoking (Grinspoon, 2009).  
HIV infection activates the inflammatory pathways that change the endothelial 
cells to prothrombotic from their phenotype, which result in increased carotid intima 
thickness (Dagogo-Jack, 2008). This phenomenon occurs as a consequence of the direct 
activation of the endothelial cells by HIV and explains why HIV increases the risk for 
CVD (Dagogo-Jack, 2008). Similarly, in HIV-infected individuals, tumor-necrosis factor 
(TNF) Receptors 1 and 2, high sensitive C-reactive protein, and abnormal fat distribution 
contribute to impaired glucose homeostasis (Brown, Tassiopoulos, Bosch, Shikuma & 
McComsey, 2010). Metabolic dysfunction such as dyslipidemia, lipodystrophy, insulin 
resistant, and diabetes occur as a result of the administration of antiretroviral therapy 
(Dagogo-Jack, 2008). 
Adverse metabolisms according to Steinhart & Emons (2004) lead to the 
development of hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein 
cholesterol levels, high low-density lipoprotein cholesterol level, insulin resistance, and 
hyperglycemia. These are components of metabolic syndrome and they present 
challenges in the treatment process, and also creates a burden on the finances of these 
individuals (Steinhart & Emons, 2004). Although several studies on metabolic syndrome 
in HIV-positive patients on HAART, and the risk of CVD has been conducted in Brazil, 
Denmark, Taiwan, the United States, Ethiopia, and Cameroon, similar studies are limited 
in Nigeria. A few studies in the northeastern and northwestern Nigeria examined the 
relationship between HAART and metabolic syndrome, with a view of its effect on 
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cardiovascular health in HIV-positive patients (Denue, Muazu, Gashau, Mbo, and Ajayi, 
2012; Muhammad et al., 2013; Ogundahunsi, Oyegunle, Ogun, Odusoga, & Daniel, O. J., 
2008). However, such studies are yet to be conducted in Umuahia metropolis. Hence, this 
study sought to fill this gap in the existing literature and examine the relationship 
between HAART regimen and hypertension, obesity, diabetes as metabolic syndrome 
components with a view to identifying the risk of CVD among HIV-positive adults 18 
years and older on HAART in this study area (Federal Medical Centre, 
Umuahia,southeast Nigeria).  
Purpose of the Study 
The purpose of this retrospective quantitative study was to examine the 
relationship among HAART regimen and hypertension, obesity, and diabetes as 
metabolic syndrome components among HIV-positive patients 18 years and older, after 
ruling out the presence of these three variables at baseline. I also sought to examine the 
relationship among duration of HAART regimen and hypertension, obesity, and diabetes 
as metabolic syndrome components after controlling for age, gender, and CD4+ cell 
count. To determine the prevalence of hypertension, obesity, and diabetes as metabolic 
syndrome components among HIV-positive patients 18 years and older attending the 
clinic at the Federal Medical Centre, Umuahia Abia State, Nigeria, I used medical chart 
reviews including baseline data.  
This study’s findings will help identify cardio metabolic risk factors attributed to 
the side effects of antiretroviral therapy. I hope that this study will contribute to 
preventing additional burdens of chronic diseases such as hypertension, obesity, and 
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diabetes in the study population through intervention programs, and I hope the findings 
will help reduce the cost of health care; encourage positive, healthy lifestyles; and 
improve the quality of life of HIV-positive patients on HAART.  
Research Questions and Hypotheses 
I attempted to answer two main research questions and sub questions, with 
corresponding research hypotheses (Ha), and null hypotheses (H0) as listed below.  
RQ1: Type of HAART Regimen 
RQ1A: Is there an association between HAART regimen and elevated blood pressure 
(hypertension) as a metabolic syndrome component among HIV-positive patients 18 
years and older in Umuahia, southeast Nigeria? 
H0: HAART regimen does not increase the odds of hypertension. 
Ha: HAART regimen increases the odds of hypertension.  
RQ1B: Is there an association between HAART regimen and obesity as a metabolic 
syndrome component among HIV-positive patients 18 years and older in Umuahia, 
southeast Nigeria?  
H0: HAART regimen does not increase the odds of obesity. 
Ha: HAART regimen increases the odds of obesity.  
RQ1C: Is there an association between HAART regimen and elevated blood glucose 
level (hyperglycemia) as a metabolic syndrome component among HIV-positive patients 
18 years and older in Umuahia, southeast Nigeria? 
H0: HAART regimen does not increase the odds of hyperglycemia. 
Ha: HAART regimen increases the odds of hyperglycemia.  
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RQ2: Duration of HAART Regimen 
RQ2A: Is there an association between duration of HAART regimen and hypertension 
among HIV-positive patients 18 years and older in Umuahia, southeast Nigeria? 
H0: Duration of HAART regimen does not increase the odds of hypertension. 
Ha: Duration of HAART regimen increases the odds of hypertension. 
RQ2B: Is there an association between duration of HAART regimen and obesity among 
HIV-positive patients 18 years and older in Umuahia, Southeast Nigeria? 
H0: Duration of HAART regimen does not increase the odds of obesity. 
Ha: Duration of HAART regimen increases the odds of obesity.  
RQ2C: Is there an association between duration of HAART regimen and elevated blood 
glucose (hyperglycemia) level among HIV-positive patients 18 years and older in 
Umuahia, southeast Nigeria? 
H0: Duration of HAART regimen does not increase the odds of hyperglycemia. 
Ha: Duration of HAART regimen increases the odds of hyperglycemia.  
Theoretical Foundation and Conceptual Framework 
Epidemiological studies are prompted by observations of events and phenomena 
that explore relationships between hosts (Kamanger, 2012). These could be chemical, 
physiological or biological factors. Epidemiological studies focus on looking for causes 
of diseases by linking exposures to risk of developing diseases (Kamanger, 2012). Thus, 
investigational studies involving infectious diseases such as HIV/AIDS focus on a single 
causal factor. However, the situation is different with chronic diseases that focus on the 
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relationship between several factors such as environmental, host behaviors, and 
physiological changes (McKenna & Collins, 2010). According to the University of 
Toronto (n.d.), HIV disease is also being viewed as a chronic, long-term disease that has 
been evaluated by the rising prevalence of disability among HIV-positive patients.  
HIV is a multisystem infection that affects different systems of the body such as 
the cardiorespiratory, the musculoskeletal, and neurological systems (University of 
Toronto, n.d). HIV infection is further complicated by antiretroviral therapies including 
HAART, which cause undesirable side effects, thereby affecting the day-to-day activities 
and quality of life of HIV-positive patients (University of Toronto, n.d). As a result, to 
prevent or delay chronic diseases attributed to the side effects of HIV infections and 
antiretroviral therapy, it is recommended that intervention programs that include lifestyle 
and behavioral changes be developed (CDC, n.d.).  
The physiologic changes that predispose infected patients to the development of 
CVD as a result of exposure to HAART are described by the metabolic syndrome theory 
(American Diabetes Association [ADA], n.d.). Metabolic syndrome theory is the 
foundation on which this study was based. Reaven (1988) proposed the metabolic 
syndrome theory first by describing the metabolic and physiologic changes observed in 
patients with diabetes type 2 diabetes mellitus (DM2) that leads to CVD. The syndrome 
is based on malfunctioning of insulin in the body system that results in insulin resistance. 
Furthermore, the observed association between obesity and hypertension attracted the 
inclusion of increased risk of hypertension in obese individuals in the metabolic 
syndrome theory. Also, Wilcox (2005) posited that changes in protein metabolism, fat 
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metabolism, and elevated blood sugar levels were responsible for insulin resistance. 
Thus, metabolic syndrome is characterized by elevated blood sugar levels, elevated blood 
pressure, enlarged waist circumference, elevated triglyceride levels, and low HDL 
cholesterol (Alberti et al., 2009; Wilcox, 2005). I discuss the metabolic syndrome theory 
further in Chapter 2.  
The positivistic theoretical approach that uses deductive reasoning was also a 
framework for this study (Institute of Medicine [IOM], 2003a, p. 2). I discuss this topic 
further in Chapter 2. The deductive reasoning focuses on the relationships between 
variables such as the environment and the individuals’ health (Liehr & Smith, 1999). 
These approaches promote the identification of challenges encountered in the treatment 
process and encourage the development of programs that promote positive behavioral 
changes that lead to healthy lifestyles. 
Nature of the Study 
This study was a quantitative, cross-sectional study. Quantitative studies focus on 
establishing relationships between the independent and dependent variables (Creswell, 
2009). This study is in line with the focus of quantitative studies to determine the 
prevalence of hypertension, obesity, diabetes as metabolic syndrome and examined the 
association among HAART regimen and hypertension; HAART regimen and obesity; 
and HAART regimen and diabetes among HIV-positive patients 18 years and older in 
Umuahia, southeastern Nigeria. This study used the observational study design and cross-
sectional data collection method. This study was a retrospective study of prospectively 
collected data of HIV-positive patients 18 years and older managed for HIV infection 
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between January 2009 and January 2013 at the Federal Medical Centre, Umuahia, Abia 
State, Nigeria. According to Hess (2004), in retrospective studies, the baseline state, 
intervention, and outcome are collected from existing data collected for purposes other 
than the study. I used the observational study design because it is a quantitative option 
that enables the comparison of pre-existing groups (HAART and non-HAART) 
retrospectively without doing any intervention (Al Amoor, 2013). I chose a cross-
sectional design because the study determined the prevalence of hypertension, obesity, 
and diabetes as metabolic syndrome components, and I collected samples from the 
population at the one-time point only (Crosby, Diclemente, & Salazar, 2006). The 
secondary data of patients’ treatment record included information at baseline before 
antiretroviral therapy (ART) initiation, previous laboratory results, ART history, clinical 
manifestations of metabolic syndrome, and sociodemographic characteristics. The 
methods used for the study was adapted from the studies of Berhane et al. (2012); Denue, 
Muazu, Gashau, Mbo, & Ajayi (2012); Diouf, Cournil, BaFall, Ngom-Gueye, Eymard-
Duvernay et al. (2012); Muhammad et al. (2013); and Tadewos, Addis, Ambachew, & 
Banerjee, (2012). I discuss the methods in detail in Chapter 3.  
I divided my target population into four strata (those cases not on HAART, those 
on HAART for 6 months, 12 months, and those on HAART for >12 months) from where 
I collected my samples. I used the pre or non-HAART cases as controls. The 
proportionate stratified random sampling was employed. This stratified technique 
required dividing the population into subgroups or strata, and then the final subjects 
selected consecutively from the different strata (Explorable.com, n.d.).  
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Using the G*Power 3.1.9.2 statistical power analysis software, the z test, logistic 
regression statistical test, binomial distribution, a power of 0.80, α of 0.05, and effect size 
(as odds ratio) of 2.333333, I calculated the sample size to be 186. I made up the sample 
size to 192 and then allocated 48 subjects to each stratum (Berhane et al., 2012). I chose 
the effect size as odds ratio because the dependent variable in the study is binary (Wilson, 
2015). 
I used Statistical Package for Social Sciences (SPSS) version 23 to analyze my 
data, and I used descriptive statistics to determine the prevalence of metabolic syndrome 
components. Furthermore, I used multiple logistic regressions to examine the association 
between HAART regimen and the metabolic syndrome components. I used multiple 
logistic regressions because according to Szklo and Nieto (2014), multiple logistic 
regression is used to examine relationships between the predictor variables, and the 
outcome (dependent) variables while allowing the control for possible confounders. 
Multiple logistic regressions are also used when the dependent or outcome variable is 
binary (Szklo & Nieto, 2014). In this study, the outcome of interests is presence or 
absence of hypertension; presence or absence of obesity; presence or absence of diabetes 
mellitus.  
The metabolic syndrome components (hypertension and diabetes) were defined 
according to the guidelines of the National Cholesterol Education Program (NCEP) ATP 
III (Grundy, et al., 2005), whereas obesity was defined according to WHO (2015) criteria. 
The following criteria were used: (a) elevated blood pressure of  ≥130/≥85 mm Hg or 
treatment for hypertensive; (b) BMI ≥25kg/m2 is overweight; BMI ≥30kg/m2 are obese; 
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(c) fasting blood glucose >100 mg/dL, or antidiabetic treatment. The dependent variables 
(hypertension, obesity, diabetes) were categorized as presence = yes or absence = no. The 
independent variables were categorized as pre-HAART, HAART regimen at 6 months, 
HAART regimen at 12 months, and HAART regimen >12 months. The measures 
included fasting blood glucose test, blood pressure measurement, and weight and height 
measurements. I included age, gender, and CD4+ cell count as confounding variables.  
Statistical significance of odds of those with metabolic syndrome components and 
those without a component were determined by p < .05 and 95% CIs. Rejection of the 
null hypotheses supported statistical significance for hypertension, obesity, and diabetes. 
I provided details of the methods in chapter three. 
Definitions 
I used the following definitions in this study: 
Highly active antiretroviral therapy (HAART): A cocktail of a minimum of three 
classes of antiretroviral drugs─PIs, nonnucleoside reverse transcriptase inhibitors 
(NNRTIs), and nucleoside reverse transcriptase inhibitors (NRTIs). 
 Metabolic syndrome (MetS): MetS is a combination of any three of the five 
metabolic syndrome components (hyperglycemia, hypertension, hypertriglyceridemia, 
low HDL cholesterol, and central obesity) (Grundy et al., 2005). 
Hyperglycemia: Hyperglycemia as defined by the ATP III guidelines is elevated 
blood glucose level above 100 mg/dL (NCEP, 2002). 
Hypertension: Hypertension as defined by ATP III guidelines is elevated blood 
pressure greater or equal to 130/85 (NCEP, 2002). 
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Obesity: Obesity was defined as BMI ≥ 30 kg/m2 (WHO, 2015). 
Assumptions 
The first assumption in this study was that data is an accurate representation of the 
HIV population in Umuahia metropolis because of the location of the study center, and 
the population of clientele that patronizes the center (Federal Medical Centre, Umuahia). 
The hospital is a tertiary hospital that has an antiretroviral therapy clinic (ART clinic) that 
serves as a referral center for several communities, from where patients requiring ART 
care are referred (FMC Umuahia, 2014). The second assumption was that data on 
hypertension, obesity, and diabetes would be available in the patients’ treatment charts in 
the medical records (FMC Umuahia, 2014). Laboratory test results were abstracted 
directly from the medical records. A third assumption was that blood pressure, weight, 
height, and blood glucose level tests were measured at baseline and thereafter. A fourth 
assumption was that blood glucose tests results were documented with the fasting test 
status according to the WHO recommendation (WHO, 2006).  
Scope and Delimitations 
This study was limited to and dependent on previously collected data from 
patients’ treatment records to establish the prevalence of hypertension, obesity, and 
hyperglycemia; and the relationship between HAART and diabetes, HAART and obesity, 
and HAART and diabetes. In addition, the study was dependent on information 
documented during the examination at baseline. This study was further limited to the 
frequency of laboratory investigations in line with the frequencies of patients’ visits to 
the clinic. With regard the dependent variables (hypertension, obesity, and diabetes); the 
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study was limited to the definition by ATP III and WHO guidelines, as well as the 
antiretroviral drug combination used in the facility. The study was also limited to markers 
of metabolic syndrome components such as hyperglycemia, and hypertension, as well as 
the CD4 cell counts, weight measurements, and height measurements. Covariates were 
limited to gender, age, and CD4+ cell count.  
The study population included HIV-positive patients 18 years and older who 
attended the ART clinic in FMC, Umuahia, southeast Nigeria between January 2009 and 
December 2013. The outcome of this study may be generalizable to the infected 
population in Nigeria. Muhammad et al. (2013) used the HAART regimens that are 
mostly used in sub-Saharan Africa in their study. They reported that their cohort study 
was representative of the participating community. Similarly, this cohort study will use 
the same HAART regimen.  
Limitations 
The limitations that apply to retrospective cohort studies also apply to this study. 
Also applicable are the limitations that apply to medical chart reviews (Hess, 2004; Wang 
et al., 2010). These limitations include reliance on information provided by patients on 
family history and accuracy of documented records of patients. These could lead to recall 
bias. In addition, incomplete critical data such as laboratory test results could be a 
limitation in this study (Hess, 2004); selection bias as a consequence of the relationship 
between exposed and unexposed patients to the outcome of interest (Aschengrau & 
Seage, 2008, p. 267). According to Aschengrau and Seage, in retrospective cohort 
studies, selection bias occurs when the outcome of interest is related to the exposed and 
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unexposed individuals. Other limitations would include difficulty in controlling 
confounders and bias as a result of nonrandomization and blinding (Hess, 2004). 
However, these limitations can be managed. To minimize loss of validity and loss of 
reliability caused by selection bias, I used the same criteria for the selection of cases and 
controls, and I managed bias due to nonrandomization by using a control group made up 
of individuals with diseases (Aschengrau & Seage, 2008, p. 282). 
Significance 
This study is unique because it addressed an area of research that focuses on the 
relationship between HAART and metabolic syndrome components, which has been 
understudied in southeastern Nigeria. The burden would be enormous if HIV-infected 
individuals come down with other chronic diseases such as hypertension, diabetes or 
hyperlipidemia that are characteristics of metabolic syndrome, and risk factors for CVD 
(Palios, Kadoglou, & Lampropoulos, 2012). In addition, having to treat the additional 
chronic illnesses not only poses problems in the treatment process but can be an 
enormous financial burden for the individual (CDC, 2013). Thus, the results obtained in 
this study could provide insights into the factors that contribute to developing metabolic 
syndrome in HIV-infected individuals, with a view of developing intervention programs 
on lifestyle changes (diet and exercise) to prevent metabolic syndrome while on 
antiretroviral drugs. These intervention programs could minimize the risk for 
cardiovascular disease, reduce patients’ medical expenditures, and cost of health care 
generally, thereby promoting positive social change by improving the quality of life of 
these groups of individuals.  
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Summary 
The management of infected patients and reduction of HIV/AIDS epidemic in the 
developing nations using HAART is not without a price (Denue et al., 2012). The price 
includes metabolic abnormalities. These lead to certain risk factors for CVD (Paula et al., 
2013). Metabolic syndrome components (hypertension, obesity, diabetes, elevated 
triglycerides ≥150 mg/dL, low HDL cholesterol <40 mg/dL in men, <50 mg/dL in 
women) are increasingly becoming important factors in the treatment of HIV-positive 
patients globally (Paula, Falcão, & Pacheco, 2013; Subbaraman, Chaguturu, Mayer, 
Flanigan, & Kumarasamy, 2007). Wu et al. (2012) found in their study that a metabolic 
syndrome was developed in about a quarter of HIV-infected patients on HAART. 
However, there may be variations in the distribution of the adverse effects of metabolic 
syndrome between developed and developing nations (Subbaraman et al., 2007). These 
differences distribution are due to host genetic makeup (Subbaraman et al., 2007), diet, 
physical inactivity, and obesity (Paula et al., 2013) as independent risk factors for 
metabolic syndrome. Although there is the consensus that metabolic syndrome 
components are modifiable and associated with HAART regimen and cardiovascular 
disease, several studies showed that the relationship between HAART and metabolic 
syndrome components differs in diverse populations and regimen (Razzouk & Muntner, 
2009; Rosolova & Nussbaumerova, 2011; Wu et al., 2012). Identification of risk factors 
could form the basis to develop and provide intervention programs for the target 
population. Thus, this study examined the relationship between types of HAART regimen 
and hypertension, types of HAART regimen and obesity, and types of HAART regimen 
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and hyperglycemia. The study also examined the relationship among duration of HAART 
regimen and hypertension, duration of HAART regimen and obesity, and duration of 
HAART regimen and hyperglycemia among HIV-positive adults 18 years and older in 
Umuahia, southeastern Nigeria. I conducted this study with a view of identifying the risk 
of CVD in HIV-positive adults on HAART in this study area to inform preventive 
interventions that could promote positive social change. The prevalence of hypertension, 
obesity, and diabetes was also determined.  
I review the literature that includes the framework that directed the study in 
Chapter 2. I also discuss studies that demonstrate the prevalence of hypertension, obesity, 
and diabetes among the HIV-positive population on HAART in Chapter 2. In addition, I 
review recent literature that demonstrates the association among HAART, hypertension, 
hyperglycemia, and obesity as metabolic syndrome components in Chapter 2. 
Furthermore, I discuss in detail studies that used secondary data and I describe their 
methods in Chapter 2. 
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Chapter 2: Review of the Literature 
HAART considerably increases the risk for MetS and CVD in HIV-infected 
patients (Kiage et al., 2013; Tadewos et al., 2012). The prevalence of metabolic disorders 
is on the increase (Berhane et al., 2012; Muhammad et al., 2013). The increasing 
prevalence has made management of HIV infection with HAART a cause for concern 
globally (Paula et al., 2013; Subbaraman et al., 2007). Risk factors for metabolic 
syndrome components include HAART regimen, duration of HAART regimen, age, and 
gender (Grinspoon, 2009). Other modifiable risk factors for metabolic syndrome 
components include smoking status, physical inactivity, diet, and obesity (Paula, Falcao, 
& Pacheco, 2013). Cross-sectional studies confirmed that metabolic syndrome 
components are prevalent among HIV-positive patients on HAART in Nigeria 
(Muhammad et al., 2013) and other developing nations (Berhane et al., 2012; Malangu, 
2014; Tadewos et al., 2012). However, there has not been any study on the analysis of the 
relationship between HAART and metabolic syndrome in this study population in 
Umuahia metropolis to date.  
The purpose of this study was to: (a) examine the relationship among types of 
HAART regimen and hypertension, obesity, and diabetes mellitus among HIV-positive 
patients 18 years; (b) examine the relationship between duration of HAART regimen and 
hypertension, obesity, and hyperglycemia as components of metabolic syndrome among 
HIV-positive patients 18 years; (c) determine the prevalence of hypertension, obesity, 
and hyperglycemia as components of metabolic syndrome among HIV-positive patients 
25 
 
18 years and older attending the clinic at the Federal Medical Centre, Umuahia southeast 
Nigeria.  
In this literature review, I present the hypothetical model approach that promotes 
the approach to the practice of public health (Institute of Medicine [IOM], 2003). This 
approach provides the foundation for the application of theories at the individual level 
and the population level (IOM, 2003). In the hypothetical model, it is assumed that all 
exposures and disease outcome are linked (IOM, 2003). In this chapter, I present the 
metabolic syndrome theory that explains the relationship among HAART, hypertension, 
obesity, and hyperglycemia, and the relationship among duration of HAART regimen, 
hypertension, obesity, and diabetes mellitus (American Diabetes Association [ADA], 
n.d.).  
I review studies that demonstrate the prevalence of hypertension, obesity, and 
diabetes mellitus as components of metabolic syndrome among the HIV-positive 
population on HAART. Recent literature that demonstrates the association between 
HAART, hypertension, obesity, and diabetes mellitus as components of metabolic 
syndrome are discussed as well in this chapter. Details of studies that used secondary data 
and that described their methods are also reviewed in this section. The dependent 
variables are hypertension, obesity, and hyperglycemia (presence or absence of each of 
the variables). The independent variables are HAART regimen and duration of HAART 
regimen (HAART at 6 months, HAART at12 months, and HAART >12 months). 
Confounding variables include age, gender, and CD4+ cell count. I also discuss the gaps 
in knowledge and how this study proposes to address the gaps and improve the overall 
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health of HIV-positive patients on HAART in this chapter. Finally, I summarize the 
sections of Chapter 2 in the summary section.  
Literature Search Strategy 
Search strategies used for this literature review included peer-reviewed journal 
articles retrieved from Google advanced search engine, published lectures, dissertations 
retrieved from Walden University Library, and databases such as PubMed, MEDLINE, 
and Cumulative Index to Nursing & Allied Health Literature (CINAHL). Key search 
terms included prevalence, HAART, diabetes, metabolic syndrome, and HIV-infection. 
The search terms were used individually as well as in combinations. Only peer-reviewed 
articles from databases that returned abstracts of articles in the past 5 years with search 
key terms were included. Using the previous 5 years range was to ensure relevant 
reviews. However, articles from databases that returned abstracts beyond five years 
related to theoretical framework and constructs were included. The search was further 
narrowed down by adding the words Umuahia, Abia state Nigeria. Queries of peer-
reviewed articles 2009 and beyond that returned recent relevant studies related to the 
prevalence of diabetes, hypertension, obesity, metabolic syndrome, HAART, and HIV 
infection were included. Further scanning of article titles returned several other relevant 
articles for full-text reviews with authors, references, and publications. 
Theoretical Foundation and Conceptual Framework 
The first step in identifying factors that affect health is by conducting 
epidemiological studies which are prompted by observational phenomenon and events 
(Kamanger, 2012). These events could be triggered by biological, chemical, or 
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physiological factors found in the physical environment. As a result, observational 
studies focus on exposures and disease occurrence by exploring the different associations 
found among variables. The associations include the relationship between disease-
causing agents, host and the environment (epidemiology triangle) as regards infectious 
diseases (Ferng, n.d., p 4). Conversely, as regards chronic diseases, the focus is on the 
physiologic changes of the host that occur as a result of the relationship between host 
behavior and the environmental factors (McKenna & Collins, 2010). A combination of 
theories that include the “systems theory” and the metabolic syndrome theory were used 
in this review.  
The CDC’s “systems theory” has its focus on understanding the fundamental 
interactions of all the different make-ups of the system (Ferng, n.d., p 5). The system is 
said to be made up of the agent, host characteristics, and environmental factors 
(epidemiology triangle) (Ferng, n.d., p 5). In this system, the agents are classified into 
biological, chemical, and physical; while the factors that affect the susceptibility of the 
individual to causative agents include gender, lifestyle, race, socioeconomic status, and 
age (Ferng, n.d., p 5). Furthermore, the theory of chronic diseases in the population is 
also supported by observational studies (IOM, 2003b). However, regarding chronic 
diseases, this theory provides the foundation that chronic diseases evolve from exposures 
to a combination of genetic, behavioral, and environmental factors (IOM, 2003b). The 
rates and types of chronic diseases may differ across populations due to genetic and 
behavioral characteristics peculiar to the different populations (IOM, 2003b). These 
various features play significant roles in influencing the disease risk factors in 
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populations, which in turn provoke series of events that leads to morbidity and mortality 
if not prevented. Hence, public health focuses on interrupting the chain of events that 
leads to morbidity and mortality through ecological epidemiology studies using exposure 
data (IOM, 2003b).  
In summary, the “systems theory” examines the different components or factors 
that influence health at the population level (Ferng, n.d., p 5). Since individuals make up 
populations, the same environmental and societal factors affect individual behavior. 
Thus, social, economic status, age, ethnicity, geographic location, gender, and economic 
policies influence individual health by shaping individual behavior (Kaplan, 1989). 
Although there is knowledge on the theoretical concepts of individual health about 
population health, there is the need to close the gap that exists in the understanding of 
why there are variations in the rates of chronic disease (Kaplan, 1989). Researchers 
conducted epidemiologic studies to compare and contrast risk factors that are associated 
with chronic diseases in populations to fill this gap. Population level intervention 
programs that target reduction of chronic diseases are then developed based on the 
outcomes of the epidemiologic studies.  
Metabolic Syndrome Theory 
The metabolic syndrome theory is based on the clustering of metabolic 
abnormalities that increase the risk of CVD (Alberti et al., 2009; Grundy, Brewer, 
Cleeman, Smith, & Lenfant, 2004; Mente, Yusuf, Islam, McQueen, Tanomsup et al., 
2010). According to Reaven (1988), hypertension, dyslipidemia, and hyperglycemia are 
among several risk factors that cluster together in most cases. Reaven observed that this 
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type of clustering is a complex system composed of several individual risk factors for 
CVD, and named it Syndrome X. Reaven however excluded central obesity as a 
component of syndrome X. In contrast to Reaven’s observation of the clustering of 
metabolic risk factors, other researchers used the term metabolic syndrome (Alberti et al., 
2009; Grundy et al., 2006; Mente et al., 2010). Reaven postulated that insulin resistance 
underlies Syndrome X and then used the term “insulin resistance syndrome” (Reaven, 
1988). After that, Reaven proposed that the clustering of metabolic syndrome 
components: increased levels of triglyceride, low levels of high-density lipoproteins, 
glucose intolerance, increased levels of low-density lipoproteins, and increased blood 
pressure increased the risk of CVD. Epidemiological studies showed that metabolic 
syndrome occurs in different ethnic groups (Stem, 1997; Zimmert, 1992). 
Metabolic syndrome is characterized by elevated blood pressure (hypertension), 
hyperglycemia (elevated blood sugar levels), obesity, and dyslipidemia (abnormal lipid 
levels) (Alberti et al., 2009; Grundy et al., 2004; Grundy, 2006). In defining metabolic 
syndrome, several criteria that included clinical outcomes, therapeutic interventions, 
metabolic components, the risk for clinical outcomes, clinical criteria for diagnosis and 
pathogenesis were considered (Grundy et al., 2004). According to the National 
Cholesterol Education Program (NCEP) (2002), it was viewed that the main clinical 
outcome of metabolic syndrome is the CVD and that several risk factors were observed in 
persons that developed CVD (Grundy et al., 2004). The 1979 Framingham study showed 
that hyperglycemia and hypertension increased the risk for CVD (Kannel & McGee, 
1979). Thus, a conclusion drawn from the Framingham study was that there is a greater 
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risk of developing adverse clinical conditions when multiple risk factors are involved 
than when only a single risk factor is involved (Framingham risk equation) (Grundy et 
al., 2004).  
Abnormalities of adipose tissue, obesity, and insulin resistance are said to be 
potential causes of metabolic syndrome (Villamar, Albuja, & Salas, 2011). Independent 
factors such as molecules of hepatic origin, immunologic origin, as well as the vascular 
origin are also said to mediate metabolic syndrome components (Villamar, Albuja, and 
Salas, 2011). However, it is said that both genetic and acquired factors regulate each risk 
factor for metabolic syndrome. According to Grundy et al. (2004), metabolism of 
lipoprotein is strongly modulated by variations in the genes. These variations in genes 
result in the dyslipidemia being expressed in response to obesity or insulin resistance. In 
the same vein, blood sugar levels are regulated by the insulin-secretory capacity and 
insulin sensitivity. Other independent contributory factors that mediate metabolic 
syndrome components include hormonal changes, aging, and pro-inflammatory state 
(Grundy et al., 2004).  
Reaven (1988) observed the association between elevated blood pressure and 
hyperinsulinemia. He also noted that there was an association between hypertension and 
obesity that was frequent (Reaven, 1988). This frequent association according to Reaven 
was attributed to fluid retention and increase in circulating catecholamine produced in 
hyperinsulinemia, as a result of the over stimulation of the sympathetic nervous system. 
On the other hand, Kaplan’s attention was on the relationship between DM2 and body fat 
distribution (Kaplan, 1989). Kaplan attributed abdominal/central obesity or adiposity to 
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the association between DM2, body fat distribution, hypertriglyceridemia, and 
hypertension. Kaplan further argued that the incidences of DM2 and CVD are increased 
by abdominal obesity (Kaplan, 1989). Furthermore, Wang, Goalstone, and Drazin (2004), 
linked the limited ability of insulin to confer protection on blood vessels from forming 
atherogenic plaque to the association between hypertension and insulin resistance. 
According to Grundy et al. (2004), insulin resistance may lead to elevated blood pressure 
through different mechanisms. Also, production of low-density lipoprotein triglycerides 
is enhanced by hyperinsulinemia which subsequently increases triglycerides levels. 
Definitions of Metabolic Syndrome 
The WHO (1999) provided a working definition of metabolic syndrome as the 
presence of insulin resistance identified by: DM2, impaired fasting glucose or impaired 
glucose tolerance in addition to any 2 of the following: High blood pressure (≥140 mm 
Hg systolic or ≥90 mm Hg diastolic) and/or antihypertensive medication, plasma 
triglycerides ≥150 mg/dL (≥1.7 mmol/L), HDL cholesterol ≥35 mg/dL (0.9 mmol/L) in 
men or ≥39 mg/dL (1.0 mmol/L) in women, BMI ≥30 kg/m2 and/or waist-hip ratio >0.9 
in men, >0.85 in women, and microalbuminuria (Urinary albumin excretion rate) ≥20 
µgm/minute (WHO, 1999). WHO defined type 2 diabetes mellitus as fasting glucose 
>126 mg/dl (7.0 mmol/L) and a 2-hour oral glucose tolerance test (2-h OGTT) ≥200 
mg/dl (11.1 mmol/L); impaired glucose tolerance (IGT) as normal fasting and a 2-hour 
oral glucose tolerance test ≥140 mg/dL (7.8 mmol/L).  
The International Diabetes Federation (IDF), 2006) defined metabolic syndrome 
based on the presence of increased waist circumference (abdominal obesity) in addition 
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to at least two of five of metabolic syndrome components. In defining abdominal obesity, 
IDF took the different ethnic groups into account. The European men whose waist 
circumferences are ≥94 cm (37 inches) and European women with waist circumferences 
≥80 cm (31.5 inches) are considered as having abdominal or central obesity (IDF, 2006). 
However, central obesity was defined differently as waist circumference ≥102 cm (40 
inches) in European men and ≥88 cm (35 inches) in European women; ≥90 cm (35 
inches) in Asian American men and ≥80 cm (32 inches) in Asian American women by 
the American Heart Association (AHA) and the National Heart, Lung, and Blood 
Institute (NHLBI) (American Heart Association, 2014). Similarly, Adult Treatment Panel 
(ATP) III (National Cholesterol Education Program (NCEP) (2002) defined metabolic 
syndrome as the presence of any three of the five components of metabolic syndrome 
without attributing any preference to any of the metabolic syndrome components. These 
observed differences in the definition of metabolic syndrome created challenges in the 
evaluation of the association between DM2 and metabolic syndrome within and across 
populations (IDF, 2006). However, the ATP III guidelines with ethnicity-specific values 
of waist circumference were adopted by most organizations to harmonize the criteria for 
defining metabolic syndrome (Alberti et al., 2009).  
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Table 1 
 
 New International Diabetes Federation Definition of Metabolic Syndrome Components 
 
 
Metabolic syndrome                                Cut points  
components 
 
Elevated fasting plasma glucose   (FPG) ≥100 mg/dL (5.6 mmol/L) or treatment of      
                                                       previously diagnosed type 2 diabetes 
                                                           
 
Elevated blood pressure                systolic BP ≥130 or diastolic BP ≥85 mm Hg 
                                                      or treatment of previously diagnosed hypertension 
 
Decreased HDL cholesterol          <40 mg/dL (1.03 mmol/L) in males 
                                                       <50 mg/dL (1.29 mmol/L) in females 
                                                      or specific treatment for the lipid abnormality 
 
Elevated triglyceride                     ≥150 mg/dL (1.7 mmol/L) or treatment for abnormal   
                                                      lipid level  
  
BMI                                               ≥30 kg/m2                                                  
 
 
Note. HDL= High density lipoprotein, BP= Blood pressure, FPG= Fasting plasma 
glucose, BMI = Body mass index. 
 
 Source: Adapted from International Diabetes Federation (2006) 
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Table 2 
 
ATP III Definition of Metabolic Syndrome Components  
 
Risk Factor                     Measurement                              Cut Points 
                                     
Waist circumference          Men                                      >102 cm (≥40 inches) 
central obesitya                  Women                                  >88 cm (≥35 inches) 
     
 
Elevated blood pressurea    Systolic blood pressure        ≥130 mm Hg  
                                           Diastolic blood pressure       ≥85 mm Hg 
 
Low HDL cholesterola       HDL cholesterol 
                                            Men                                      < 40 mg/dl (<1.03 mmol/l) 
                                            Women                                 < 50 mg/dl (<1.29 mmol/l) 
 
Elevated triglyceridesa       Triglycerides                          ≥150 mg/dl (>1.7 mmol/l)  
Elevated fasting glucose    Fasting glucose 
                                            Currentb                                  ≥100 mg/dl (>5.6 mmol/l) 
                                            Formera                                   ≥110 mg/dl (>6.1 mmol/l) 
 
 
Note. ATP III = Third Adult Treatment Panel, cm = centimeters, mm Hg = millimeters  
 Mercury, mg/dl = milligrams per deciliter, HDL = high-density lipoprotein, mmol/l =  
millimoles per liter. aATP III guidelines (National Cholesterol Education Program, 2002) 
bATP III guidelines modified to meet American Diabetes Association guidelines  
Source: (Alberti et al., 2009). 
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Definitions of HAART 
HAART is defined as the use of two nucleosides or nucleotide reverse 
transcriptase inhibitor (NRTI/NRTI) in combination with a non-nucleoside reverse 
transcriptase inhibitor (NNRTI), the use of two NRTIs and a protease inhibitor (PI) or the 
use of three NRTIs (Department of Health and Human Services [DHHS], 2004).  
Mechanisms of Action of HAART 
Metabolic changes such as elevated blood pressure, dyslipidemia, and insulin 
resistance, which are components of metabolic syndrome, frequently been associated 
with individuals infected with HIV on HAART (Palios et al., 2012). These metabolic 
changes have resulted in a rise in the incidence of cardiovascular disorders among HIV-
infected patients (Palios et al., 2012). According to Friis-Moller, Sabin, and Weber 
(2003), the use of HAART in HIV-infected patients has increased the risk of myocardial 
infarction by 26%.  
The adverse effect of HAART on the arterial wall is said to be the underlying 
mechanism behind myocardial infarction in HIV-infected individuals (Hsue, Hunt, & 
Wu, 2009). However, other reports have implicated HIV infection through chronic 
progressive inflammation, immunodeficiency, and endothelial cell dysfunction in the 
development of atherosclerosis (Francisci, Giannini, & Baldelli, 2009; Hsue, Hunt, & 
Schnell, 2009). It is, therefore, important to understand the underlying mechanisms of the 
HAART-induced metabolic syndrome to enable the designing of effective interventions 
to control cardiovascular diseases in this population. 
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The liver centrally regulates lipid homeostasis. It is also the first organ that 
ingested medicines including HAART come into contact (Zha, Studer, Zha, Hylemon, 
Pandak et al., 2011). The ApoE endocytosis pathway converts lipids into chylomicrons in 
the intestines, and finally ends up in the liver (Zha et al., 2011). Triglycerides (TGs) and 
cholesterol are packaged in the liver into very low-density lipoproteins (VLDL) for 
onward transport to peripheral tissues (Zha et al., 2011). Following lipase hydrolysis, 
VLDLs and TGs are then taken up by adipose tissue and muscle. The lipoproteins that are 
left known as intermediate density lipoproteins (IDL) are either converted to low-density 
lipoproteins by lipases or endocytosis by cells. Lipids and cholesterols are sent back to 
the liver by peripheral tissues to prevent overloading of LDL and signaling the liver to 
stop further production of VLDLs, proteins. However, this pathway is said to be affected 
by HAART (Zha et al., 2011).  
The activation of the inhibition of sterol regulatory element-binding protein-1 
(SREBP-1) in the liver, the protease-mediated breakdown of Apo lipoprotein-B, the 
formation of very low-density lipoproteins, and lipase activity reduction are the potential 
mechanisms underlying protease inhibitor (PI) associated dyslipidemia (Liang et al, 
2001; Ranganathan & Kern, 2002). One of the side effects of HAART is insulin 
resistance (Palios et al., 2012). According to Haugaard, Andersen, and Storgaard (2004), 
PIs affect insulin sensitivity through the IRS-1 phosphorylation and glucose uptake from 
adipocytes. Insulin signaling is mediated by the protein Akt (Zha et al., 2011). But the 
insulin signaling action is inhibited by PIs which induce cellular insulin resistance. 
Furthermore, Lee, Rao, and Grunfeld (2005) found a decrease in peripheral glucose 
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uptake with PIs use. In the same vein, lipodystrophy causes impairment of insulin 
feedback on B-cells, resulting in the dysfunction of B-cell. Thus, increase in visceral fat 
and reduction in subcutaneous fat independently contribute to hyperinsulinemia and 
insulin resistance in HIV-infected patients on HAART (Palios et al., 2012). Lipolysis 
caused by antiretroviral drugs is also another way through which insulin resistance is 
developed in HIV-infected patients on HAART (Grinspoon, 2003). 
Application of Metabolic Syndrome Theory (MST) 
The application of metabolic syndrome is very apparent in several 
epidemiological studies (Beltrán-Sánchez et al., 2013; Berhane et al., 2012; Dimodi et al., 
2014; Ervin, 2009; Feleke, Fekade, & Mezegebu, 2012; Mhlabi, 2011; Villamar et al., 
2011; Wu et al., 2012). Metabolic syndrome has been applied to studies that examined 
relationships between HAART and hypertension, obesity, diabetes.  
This study focuses on the relationship between HAART and Metabolic syndrome 
components (hypertension, obesity, diabetes). HAART causes malfunctioning of the 
metabolic system (Muhammad et al., 2013). HAART leads to insulin resistance and 
subsequently DM2 (Abebe, Kind, Belay, Gebreegziabxier, Challa et al., 2014). HAART 
also leads to abnormalities of adipose tissues that result in obesity (Villamar et al., 2011). 
Thus, adapting the MST will provide a good understanding of the relationship between 
HAART and hypertension, obesity, diabetes. 
Prevalence of Metabolic Syndrome Components 
The epidemiological construct of metabolic syndrome components in individuals 
living with HIV is associated with varying permutations of risk factors that present with 
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unique treatment strategies and clinical implications (Ferrannini, 2007). To assess the 
prevalence of metabolic syndrome and its components in populations, researchers apply 
the appropriate study design and methods such as cross-sectional study design used in 
this study. Cross-sectional studies according to (Crosby, Diclemente & Salazar, 2006) are 
used to determine the prevalence of disease within a population at a one-time point only. 
Researchers have raised concern over increased rates of metabolic syndrome and CVD in 
HIV-infected population, thereby making metabolic syndrome a major public issue   
(Biron, Bobin-Dubigeon, Volteau, Piroth, Perre et al., 2012; Ervin, 2009; Feleke et al., 
2012). Researchers reported the prevalence of metabolic syndrome components among 
HIV-positive patients, and the relationship to HAART in several population-based cross-
sectional studies  (Beltrán-Sánchez et al., 2013; Berhane et al., 2012; Diouf et al., 2012; 
Feleke et al., 2012; Sachithananthan, Loha, & Gose 2012; Wu et al., 2012). 
In Ethiopia, Sachithananthanet al. (2012) conducted a retrospective study and 
examined the prevalence of diabetes Mellitus, hypertension, and lipodystrophy in HIV 
patients receiving HAART in Sodo Government hospital in southern Ethiopia. 
Sachithananthan and colleagues recruited one hundred and seventy-six subjects from 
patients’ electronic database and analyzed data using descriptive statistics, Chi-square, 
bivariate analysis, and multivariate logistic regressions. They recorded 8% (95% CI, 4.1–
11.9) prevalence of diabetes mellitus and 15.9% (95% CI, 10.5–21.3) hypertension. They, 
however, found that the prevalence of hypertension (p = .007, COR: 5.73; 95% CI, 1.46–
22.58) in those with Lipohypertrophy was significantly higher (Sachithananthanet al., 
2012). 
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In a similar cross-sectional study in Senegal, Diouf et al. (2012)   examined the 
prevalence of diabetes and hypertension, and the relationship between diabetes, 
hypertension and antiretroviral treatment among HIV-positive patients. The authors 
found that 28.1% of the 242 subjects had hypertension while 14.5% had diabetes. Using 
multivariate logistic regressions, they also concluded that there was an association 
between diabetes and long duration of ART (≥119 months), elevated cholesterol levels, 
increased BMI, and older age. They, however, found that high triglycerides levels, 
increased BMI, and older age were associated with increased risk of hypertension.  
In Albania, Kolpepaj, Shkurti, Nake, Harxhi, Kolici et al. (2015) conducted a 
study that investigated the metabolic problems associated with HIV treatment; focusing 
on HAART –linked lipodystrophy and central obesity. The authors used multivariate 
analysis to examine the associations and found that alteration of adipocytes, amplified 
metabolic action in different adipose tissues, and imperfect lipogenesis, resulted to 
HAART-linked lipodystrophy. 
Prevalence of Metabolic Syndrome Components in Developing Countries 
According to Gaziano, Bitton, Anand, Abrahams-Gessel and Murphy (2010), 
there is an increase in the number of persons with metabolic syndrome components in 
developing countries in the past couple of decades. Gaziano et al.; Gersh, Sliwa, Mayosi, 
and Yusuf (2010); Mohan & Deepa (2006) observed the increase in the rates of morbidity 
and mortality caused by CVD. The prevalence of metabolic syndrome in developing 
countries as published by various studies ranged from 30.7% in Cameroon (Dimodi et al., 
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2014), 15% in China, 19% in Malaysia 20% in Indian using the ATP III definition of 
metabolic syndrome (Mohan & Deepa, 2006).  
In Cameroon, Dimodi et al. (2014) examined the prevalence of metabolic 
syndrome and its individual components among HIV-positive patients in a prospective 
cross-sectional study. The study was conducted with 492 infected patients 20 years and 
older on antiretroviral therapy. Findings of the study showed 32.8% and 30% prevalence 
of metabolic syndrome using the IDF and ATP III criteria respectively (p = .0001). They 
also found the prevalence of metabolic syndrome to be 36% and 23.4% in patients 
receiving HAART and HAART-naive patients (p = .0001) respectively (Dimodi et al., 
2014). The prevalence of the individual components was: abdominal obesity (40.5%; 
26.9% (IDF and ATP III respectively); hypertriglyceridemia (55.5%), low HDL 
cholesterol (42.5%), systolic hypertension (38.2%) diastolic hypertension (28.5%), and 
hyperglycemia (31.2%; 1.3% p = .0001) (Dimodi et al., 2014). The study established that 
prevalence of metabolic syndrome is dependent on the use of HAART, and the type of 
HAART used. 
Similar results were reported by Wu et al. (2012). Wu and colleagues reported 
26.2% metabolic syndrome of a total of 877 HIV-positive patients on HAART in a cross-
sectional study conducted in a hospital in Taiwan. Wu and colleagues also reported an 
association between prolonged exposure to HAART, PIs, NRTIs, and MetS (OR, 1.78; 
95% CI, 1.03–3.07); (OR, 1.96; 95% CI, 1.13–3.42), and (OR, 1.91; 95% CI 1.11–3.30) 
respectively (Wu et al., 2012).  
41 
 
Prevalence of Metabolic Syndrome Components in Developed Countries 
The prevalence of metabolic syndrome in developed countries is similar to that in 
developing countries as observed by several researchers (Beltrán-Sánchez et al., 2013; 
Ervin, 2009; Hansen et al. 2009; Lauda, Mariath, & Grillo, 2011). Ervin (2009) studied 
the NHANES data from 2003 to 2006 that examined U.S adults 20 years and older as 
participants. Ervin reported metabolic syndrome prevalence of 34%, and that metabolic 
syndrome increased with age but differed by ethnicity. Ervin concluded that metabolic 
syndrome varied by population (Ervin, 2009). Hansen et al., in a similar study reported a 
metabolic syndrome prevalence of 27% in a retrospective HIV cohort study in Denmark. 
In the same vein, Lauda et al. (2011) reported a metabolic syndrome prevalence of 20.9% 
of which 18.5% were male, and 23.5% were female in a cohort of 249 HIV-infected 
individuals 18 and older in Brazil. These studies all point to the increasing burden of 
metabolic syndrome prevalence among the HIV-positive population, and that prevalence 
cut across race/ethnicity and region both in the developing and developed nations. 
When compared with countries in the developed world, the extent and degree of 
adverse drug reactions related to HAART in developing countries have made the process 
of dealing with HAART toxicity pivotal in the care and management of HIV 
(Kumarasamy, VenKatesh, Cecelia, DeValeenal, Lai et al., 2008; Mills, Cooper, Seely & 
Kanfe, 2005). Though Wu et al. (2012); Berhane et al. (2012) reported an association 
between prolonged exposure to HAART and metabolic syndrome in Taiwan and Ethiopia 
respectively, Hansen et al. (2009) on the other hand, reported no association between the 
presence of metabolic syndrome and HAART duration in Denmark. 
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 The severity of adverse effects could be related to the high prevalence of other 
underlying disease conditions such as tuberculosis, malnutrition, anemia, and the 
concomitant use of herbal medications with some individuals presenting with advanced 
HIV disease at their initial hospital visit in developing countries (Mills, Cooper, Seely, & 
Kanfe, 2005).  
Effects of HAART on Blood Pressure   
There is growing evidences that HIV-infected patients on HAART are at greater 
risk of heart disease and stroke as a result of elevated blood pressure (Arruda Junior, 
Lacerda, Moura, Albuquerque, Filho et al., 2010; Denue et al., 2012; Palacios et al., 
2006). Blood pressure according to NHLBI (2011a) is the force the heart exerts to pump 
blood into the vascular system of the body. The heart is said to require more force to 
pump blood efficiently in the system when there is resistance in the vascular system 
(NHLBI, 2011a).  
Investigations in Maiduguri, Nigeria affirmed the high prevalence (31.7%) of 
hypertension among HIV-positive patients on HAART (Denue, et al., 2012). Denue and 
colleagues examined the impact of HAART on blood pressure after two years of 
commencement of HAART in a cohort of 227 patients. They used χ2 test or Fisher’s 
exact test to analyze categorical variables and used the paired Student’s t-test to compare 
baseline data with data 2 years after commencement of HAART. The result showed a rise 
in blood pressure with time 3.47±15.21 vs. -0.71±16.28 (p = .08), 1.81±10.12 vs. 
1.0±11.39 (p = .625) and 1.67±14.14 vs. 1.71±12.08 (p = .982). The authors thus 
suggested periodic measurement of blood pressure and treatment where necessary of 
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HIV-positive patients on HAART. Prevalence of hypertension with longer duration of 
antiretroviral use was also reported by Arruda Junior et al. (2010) in a study in Brazil. 
They also reported 25.6% hypertension prevalence, 14% pre-hypertension, and 40.5% 
normotension (controls) in the participants, and concluded that there is a need for 
measures to control factors such as unhealthy diet and excessive weight gain (Arruda 
Junior et al., 2010). Palacios et al. (2006), in a prospective study of 95 HIV-infected 
patients placed on HAART regimen reported 26% prevalence of hypertension. They 
recommended periodic measuring and treatment where necessary of HIV-infected 
patients on HAART.  
Effects of HAART on Body Fat Distribution   
Despite the benefits of HAART in reducing HIV levels in infected patients, 
exposure to HAART is said to affect body fat distribution in HIV-infected patients, and 
also increases the risk of CVD (Brown et al., 2009). The body store fat underneath the 
(subcutaneous fat), and in the viscera (Reaven, 2011). The subcutaneous fat provides 
insulation for the body, while the visceral fat provides a source of quick energy (Reaven, 
2011). Abdominal adiposity (central obesity) is said to be associated with excessive 
accumulation of visceral fat and also associated with the metabolic syndrome (Reaven, 
2011). WHO defined obesity based on the body mass index (BMI) (WHO, 2015). Obesity 
was defined as BMI ≥30kg/m2, overweight as BMI ≥25kg/m2, BMI 19-24.9kg/m2 as the 
normal range, and BMI <19kg/m2 as being underweight. BMI according to WHO (2015) 
is the weight of an individual in kilograms divided by the square of the individuals’ 
height in meters (kg/m2). 
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In Jimma, southwest Ethiopia, Berhane et al. (2012) evaluated the prevalence of 
lipodystrophy (fat metabolism disorder) and metabolic syndrome among HIV-positive 
individuals on HAART. They reported lipodystrophy prevalence of 12.1% in a sample of 
313 HIV patients 18 years and older. The study also revealed that taking the antiretroviral 
therapy for 12 months and more was associated with metabolic syndrome male (AOR = 
4.2; 95% CI = 1.24, 14.23) and female (AOR = 2.30; 95% CI = 1.0, 5.27). Berhane and 
colleagues also found that taking the antiretroviral therapy for the longer duration of 12 
months and more was independently associated with HIV-lipodystrophy (AOR = 3.59; 
95% CI = 1.03, 12.54) (Berhane et al., 2012).  
Sharma, Bynum, Schneider, Cox, Tien et al. (2014) followed 1177 HIV-positive 
women in a prospective study for 15 years to examine changes in BMI after being 
initiated on HAART regimen. The authors used the multivariate mixed-effects ordinal 
logistic regression to estimate the degree of association of exposure with post-HAART 
BMI. Sharma and colleagues reported that 39% of the women had normal BMI before the 
commencement of HAART, but 40% of them became overweight, while 47% became 
obese, and 27% morbidly obese at some point. This point to the hypothesis that duration 
of HAART increases the odds of obesity 
Effects of HAART on Glucose Metabolism  
Glucose is a source of energy to body tissues, and a major factor in metabolism 
(Merriam-Webster, 2015). It is transported into tissue cells by insulin (Merriam-Webster, 
2015). Insulin also regulates the amount of glucose that circulates in the body (Schneider, 
2014). In situations when there is insulin resistance, insulin is unable to control the 
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amount of circulatory glucose, thereby resulting in elevated glucose in the blood stream 
resulting in diabetes mellitus (Schneider, 2014). Thus, elevated blood glucose is a marker 
for insulin resistance. Insulin resistance according to Bastard et al. (2006) determines the 
production of excess adipokine leading to dysfunction of the endothelia. The endothelial 
dysfunction leads to metabolic syndrome and diabetes mellitus with a progression of 
endothelial damage (Bastard et al., 2006). Thus, the progression of endothelial damage, 
as well as thrombosis and inflammation of the endothelia results in the production of 
atherosclerotic plaques in the wall of the vessels (Bastard et al., 2006). 
Insulin resistance and increased rate of diabetes mellitus have been associated 
with HAART (Abebe et al., 2014; Brown, et al., 2005; Chukwuanukwu, Manafa, Ugwu, 
Onyenekwe, Oluboyo et al., 2013). In Nigeria, Chukwuanukwu et al. determined the 
prevalence of DM in HIV-infected patients on HAART using a sample of 150 patients. 
The patients were grouped into two groups of 50 patients each according to the drug 
regimen; first line drugs (lamivudine, nevirapine, combivir, combipack, and efavirenz ); 
second line drugs (truvada and aluvida) and a third control group of 50 patients not on 
HAART. The authors reported a prevalence of 6% diabetes mellitus with the second line 
regimen, 0% prevalence with the first line regimen, and 10% prevalence of impaired 
glucose intolerance (Chukwuanukwu et al., 2013). Similar results were reported by 
Abebe et al. (2014) in Addis Ababa Ethiopia, where they examined the association 
between antiretroviral treatment and hyperglycemia and dyslipidemia among 126 HIV-
infected patients on HAART in the Burayu health center. The results showed that 
hyperglycemia was 7.9% prevalent in the HAART initiated group and 5.6% prevalent in 
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the non-HAART group. However, they recorded no significant difference between 
HAART initiated and the HAART-naive group (p = .45). 
Similarly, Butt, McGinnis, Rodriguez-Barradas, Crystal, Simberkoff et al. (2009) 
reported 21.4% (p < .0001) prevalence of diabetes in HIV-infected patients on HAART 
compared to 14.9% HIV-infected patients at baseline in the veterans aging cohort study 
(VACS) prospective study of 3,327 HIV-infected patients and 3,240 HIV-uninfected 
subjects (controls) in the U.S. They also reported that HIV was associated with the use of 
NRTI, NNRTI therapy and that NRTI; NNRTI therapy increased the risk for diabetes in 
HIV-infected individuals (Butt et al., 2009). These reports all support the hypothesis that 
HAART increases the odds of diabetes mellitus (hyperglycemia). 
Metabolic Syndrome and Cardiovascular Disease   
The risk for CVD is substantially increased by HIV infection and HAART 
(Kingsley et al., 2008; Triant et al., 2007). Cardio-metabolic outcomes in patients living 
with HIV infections and combination antiretroviral therapy have being established by 
several studies (Kingsley, Cuervo-Rojasc, Muñozc, Palellad, Post, Budoff, Kingsley, 
Palellad, Witt et al., 2008; Post, Budoff, Kingsley, Palella, Witt et al., 2014; Triant, Lee, 
Hadigan, & Grinspoon, 2007). The independent association of the aforementioned cannot 
be overemphasized as studies have established the association of HAART with insulin 
resistance, elevated serum triglycerides (TG), low-density total and lipoprotein 
cholesterol (TC & LDL-c) (Fontas, van Leth, Sabin, Friis-Moller, Rickenbach et al., 
2004; Jones, Sawleshwarkar, Michailidis, Jackson, Mandalia et al., 2005; Passalaris, 
Sepkowitz & Glesby, 2000). Similarly, increases in the level of LDL-C has been reported 
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to be associated with the thickening of the arterial walls (atherosclerosis), CVD, coronary 
heart disease, and coronary artery disease resulting in myocardial infarction and stroke 
(Roger, 2011).  
The relationship between metabolic syndrome and CVD has been demonstrated 
by several researchers in Nigeria (Muhammad et al., 2013), Zambia (Kiage et al., 2013), 
and Addis Ababa (Feleke et al., 2012). Muhammad et al. evaluated the cardiovascular 
risks among patients on HAART in a cross-sectional study of HIV patients placed on 
HAART for six months and above, and HAART naïve group in Aminu Kano Teaching 
Hospital, Nigeria. The researchers found that there was an increased proportion of 
cardiovascular risk in individuals placed on HAART. The incidence of hypertension in 
patients exposed to HAART was approximately eight times higher when compared to the 
non-exposed, 17% and 2% respectively (p < .001) (Muhammad et al., 2013). The study 
established significant correlations in cardiovascular risk factors such as metabolic 
syndrome, obesity and hypercholesterolemia in patients treated with HAART. Kiage et 
al. on the other hand conducted a retrospective study of 210 HIV-positive patients 16.5 -
60 years old using the dataset from the diet, genetic polymorphisms in lipid-metabolizing 
enzyme genes, and antiretroviral therapy-related dyslipidaemia (DGPLEAD) in Lusaka, 
Zambia from January to December 2007. The researchers found that there was an 
association between cardiometabolic risk markers and combined anti-retroviral therapy 
regimen; changes in cardiometabolic risk markers and duration of combined anti-
retroviral therapy regimen. Furthermore, Feleke et al. (2012) explored the risk factors and 
prevalence of cardiovascular complications and chronic metabolic abnormalities in a 
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cross-sectional study in Addis Ababa. The authors reported the prevalence of 
hypertriglyceridemia as 15.2%, lipid density lipoprotein cholesterol as 54.2% and the 
prevalence of hypercholesterolemia as 38.2%. They also reported that the prevalence of 
hyperlipidemia was considerably high 56.9% (319) amongst study participants. Feleke et 
al. further established a significant association in the development of 
hypertriglyceridemia, lipohypertrophy and lipoatrophy in individuals exposed to HAART 
for duration of at least a year or more and reiterated the importance of monitoring adverse 
events in patients on HAART for metabolic abnormalities.  
Summary 
Metabolic syndrome is based on the premise that three or more of the five 
components are present (NCEP, 2002). Metabolic syndrome is composed of a 
combination of hypertension, obesity (central obesity), elevated blood sugar, and 
dyslipidemia. In this study, I used hypertension, obesity, and hyperglycemia as metabolic 
syndrome components. These components are risk factors for CVD. Although according 
to Reaven (2011), metabolic syndrome is not a risk assessment tool, it explains the 
relationships that exist between metabolic abnormalities and clinical outcomes.  
Exposure of HIV-infected individuals to antiretroviral therapy predisposes them 
to abnormal glucose metabolism and dyslipidemia, with low HDL cholesterol and 
hypertriglyceridemia predominating in HIV-related metabolic syndrome (Fontas et al., 
2004). Non standardization of measurement while capturing clinical details of patients 
give room for bias in the assessment of the prevalence of metabolic syndrome argued 
Worm, Friis-Moller, Bruyand, Monforte, Rickenbach et al. (2010). For this reason, Worm 
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et al. suggested that laboratory measurements be conducted two times consecutively and 
that prevalence of metabolic syndrome should be based on this in cohort studies. 
Assessing metabolic syndrome components in populations can go a long way in 
determining the most prevalent component. This knowledge can help form the platform 
on which effective prevention and intervention programs that adopt lifestyle changes to 
reduce the prevalence of metabolic syndrome and CVD. I discuss in detail the methods 
used in this study to determine the prevalence of hypertension, obesity, and 
hyperglycemia; and examined the relationship among HAART, hypertension, obesity, 
and hypertension as metabolic syndrome components in Chapter 3. 
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Chapter 3: Research Method 
This purpose of this retrospective quantitative study was to use medical 
records/treatment charts to examine the relationships between types of HAART regimen 
and hypertension, types of HAART regimen and obesity, and types of HAART regimen 
and hyperglycemia. The study’s purpose was also, to examine the relationship between 
duration of HAART regimen and hypertension, duration of HAART regimen and obesity, 
and duration of HAART regimen and hyperglycemia. In addition, the purpose was to 
determine the prevalence of hypertension, obesity, and hyperglycemia among HIV-
positive patients 18 years and older attending the clinic at the Federal Medical Centre, 
Umuahia, Nigeria.  
I discuss the study design and methods in this chapter. I review the research 
questions and I provide the rationale for using descriptive statistics to determine the 
prevalence of hypertension, obesity, and hyperglycemia. In this chapter, I also explain 
why I used multiple logistic regressions to examine the relationship among HAART 
regimen, hypertension, obesity, and hyperglycemia. 
 Furthermore, I detail the study population, sample, and sample procedures, and I 
describe the data collection methods and data analysis. In addition, I discuss the measures 
I took to minimize bias and strengthen the internal and external validity in this section. I 
also explain the procedures I followed to gain access to data and protect the study 
participants.  
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Research Design and Rationale 
My aim in this study was to answer two major research questions and a series of 
sub questions on the relationship among HAART regimen, duration of HAART regimen 
and hypertension, obesity, and diabetes as metabolic syndrome components.  
RQ1: Type of HAART Regimen 
RQ1A. Is there an association between types of HAART regimen and elevated 
blood pressure (hypertension) among HIV-positive patients 18 years and older in 
Umuahia, southeast Nigeria? 
RQ1B. Is there an association between types of HAART regimen and obesity 
among HIV-positive patients 18 years and older in Umuahia, southeast Nigeria? 
RQ1C. Is there an association between types of HAART regimen and elevated 
blood glucose level (hyperglycemia) among HIV-positive patients 18 years and older in 
Umuahia, southeast Nigeria? 
RQ2: Duration of HAART Regimen 
RQ2A. Is there an association between duration of HAART regimen and 
hypertension among HIV-positive patients 18 years and older in Umuahia, southeast 
Nigeria? 
RQ2B. Is there an association between duration of HAART regimen and obesity 
among HIV-positive patients 18 years and older in Umuahia, southeast Nigeria? 
RQ2C. Is there an association between duration of HAART regimen and elevated 
blood glucose level among HIV-positive patients 18 years and older in Umuahia, 
southeast Nigeria? 
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The first question focuses on the relationship among HAART regimen and 
hypertension, obesity, diabetes as metabolic syndrome components. I used the 
quantitative research methods in this study. Quantitative methods use numerical data that 
are analyzed statistically to explain phenomena that occur in the world (Burns & Grove, 
2005, p. 23.) According to Burns and Grove, this method is used to describe variables 
and determine cause-and-effect interactions between variables. Also, according to 
Creswell (2009), quantitative studies focus on establishing relationships between the 
independent and dependent variables. As in this study, HAART and duration of HAART 
are the independent variables, while hypertension, obesity, and hyperglycemia are the 
dependent variables). Also, to answer this question, the cross-sectional data that was 
collected at one point in time was the basis for determining the prevalence of 
hypertension, obesity, and hyperglycemia among HIV-positive patients in this study.  
As indicated in Chapter 1 of this dissertation thesis, the quantitative option 
enables the comparison of pre-existing groups (ART and non-ART) retrospectively 
without doing any intervention (Al Amoor, 2013). According to Crosby, Diclemente and 
Salazar (2006), cross-sectional studies that use data drawn from the population at a one-
time point only are used for prevalence studies. Furthermore, to establish whether 
HAART regimen increases the odds of high blood pressure, obesity, and hyperglycemia, 
the presence of HAART regimen before the onset of these metabolic variables, were 
observed. Likewise, the temporal association between the onset of high blood pressure, 
obesity, hyperglycemia and HAART regimen were confirmed by comparing the 
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prevalence of risk factors in the individuals who did and did not develop high blood 
pressure, obesity, and hyperglycemia (Nicholols, & Moler, 2010).  
The second question is whether there is an association among duration of HAART 
regimen and high blood pressure, duration of HAART regimen and obesity, duration of 
HAART regimen, and diabetes as components of metabolic syndrome in the study 
population. Prevention programs can be strengthened if the focus is on reducing risk 
factors that can bring about enormous health problems. As a result, knowing whether the 
duration of HAART regimen increases the odds of hypertension, obesity, and 
hyperglycemia is necessary. Thus, understanding the risk factors that predict these 
metabolic syndrome components in HIV-positive patients in Umuahia will prevent or 
delay development of metabolic syndrome components in the study population, as well as 
enable population specific intervention programs to be brought closer to the community 
(Howard, Rodriguez, Bennett, Harris, Hamman et al., 2002). 
 Relationships among HAART and high blood pressure, obesity, and 
hyperglycemia were determined by the odds ratios and the respective p - values and 95% 
CIs for each independent variable. Independent variables include HAART regimen and 
duration of HAART regimen. The independent effects of each variable on these 
metabolic syndrome components were analyzed using multiple logistic regression models 
when other covariates were controlled. It was assumed that in multiple logistic regression 
analysis, the logit (natural logarithm of the odds of the outcome) changes linearly with 
multiple independent variables. Multiple logistic regressions also assume that the 
outcome is a binomial distribution (Katz, 2006). The assumption for a binomial 
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distribution was met in this study since the outcome was presence or absence of 
hypertension; absence or absence of obesity; presence or absence of hyperglycemia. 
Furthermore, to meet the second assumption of logit changes with multiple independent 
variables, I divided continuous variables such as age into categorical groups to create 
dichotomous variables. According to Katz, multiple covariates could be categorical or 
continuous.  
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Table 3 
Study Variables 
 
Variable type       Variable name     Potential response          Level of measurement 
 
Dependent    Hypertension        Presence of hypertension = 1        Nominal 
                                                         Absence of hypertension = 0 
 
Dependent         Obesity                  Presence of obesity = 1                Nominal 
                                                         Absence of obesity = 0 
 
Dependent         Diabetes                Presence of diabetes = 1               Nominal 
                                                         Absence of diabetes = 0 
 
Independent      HAART                Lam, stav, nvp = 1 
                                                        Comb, nvp = 2                              Nominal 
                                                        Comb, efv =3                                                            
                                                        Truv, efv = 4  
 
Independent    Duration of          Pre HAART = 0 
                           HAART               <6 months = 1 
                                                        6–12 months = 2                          Nominal 
                                                        >12 months = 3 
 
Covariate            Age                     18–29 =1 
                                                        30–50 = 2                                    Nominal 
                                                        >50 = 3                      
 
Covariate            Gender                Male =1                                        Nominal 
                                                       Female = 2       
 
Confounder        CD4+ cell           10–200 =1, 201–350 = 2              Nominal 
                            count                  351–500 = 3, >500 = 4 
 
Note. HAART = Highly active antiretroviral therapy, Lam = Lamivudine, stav = 
Stavudine, nvp = Nevirapine, comb = Combivir, efv = Efavirenz, Truv = Truvada. 
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In this study, I used existing data from medical charts/ records of HIV-positive 
individuals. I sought permission from the Health Research Ethics Committee of Federal 
Medical Centre (FMC) Umuahia to access the medical records of the patients, to use data. 
Medical record review according to Wickson-Griffiths, Kaasalainen, Ploeg, and McAiney 
(2014) is a method used in collecting retrospective data, collecting data for research and 
occupational therapy for performance analysis and quality assessment. The retrospective 
methodology involves looking back in time into events (Panacek, 2007) as is the case in 
this study where I will be looking into the medical records of my study population. 
According to Hess (2004), in retrospective studies, the baseline state, intervention, and 
outcome are collected from existing data collected for purposes other than the study. 
Retrospective designs are useful when evaluating or assessing palliative and end -of-life 
care, and when it’s hard or impossible to answer research questions prospectively (Hess, 
2004). 
Although the analysis of secondary data retrospectively eliminates the cost and 
time of designing, funding, and implementing compared to conducting prospective cohort 
studies; retrospective cohort studies do have some limitations or challenges (Wickson-
Griffiths et al., 2014). Some of the limitations of medical chart review in retrospective 
studies include incomplete and inaccurate documentation, incomplete data, missing 
charts, lack of binding to the study purpose, and inconsistency in the coding of chart 
information (Wickson-Griffiths et al., 2014). These limitations according to Wickson-
Griffiths et al. may threaten the overall validity and reliability of this study.  
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Population and Sampling 
This study was conducted in the Federal Medical Centre (F.M.C) Umuahia, 
southeast Nigeria. F.M.C Umuahia is a 327-bed tertiary hospital centrally located and 
easily accessible. It is the only federal hospital in Abia state. The facility draws patients 
and clientele predominantly from the southeast and south-south part of the country 
(Nwadinma, 2013). The facility provides specialized services including HIV services for 
both outpatients and inpatients. HIV services became available in Nigeria in the year 
2004. However, HIV services in the facility commenced in the year 2006. The facility 
runs an outpatient antiretroviral clinic. 
In this facility-based retrospective study, the population source was HIV-infected 
patients 18 years and older managed for HIV infection between January 2009 and 
December 2013 in F.M.C., Umuahia. Because organized antiretroviral therapy unit 
(ART) was established in January 2009, I used January 2009 as my study start date. 
Umuahia is the capital of Abia state in south-eastern Nigeria and located at latitude 5, 
5333 (531’59.988’’N) and longitude 7, 4833 (728’59.988’’E). It has a population of 
359,230 people as of the last Nigerian census in 2006 and has Igbo as the traditional 
language (The GPS Coordinates.net., n.d.). Umuahia is comprised of Umuahia North and 
Umuahia South local government areas.  
Sampling Procedures 
The method for sampling was adapted from the study of Berhane et al. (2012). 
The proportionate stratified random sampling techniques were employed. To achieve a 
representative sample of a population, it is imperative to randomly select the samples 
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(Frankfort-Nachmias & Nachmias, 2008). This stratified technique requires dividing the 
population into subgroups or strata, and the final subjects are then selected sequentially 
from the different strata (Explorable.com, n.d.). The stratified sampling technique helps 
to highlight particular subgroups within the population. It is also employed in studies that 
involve population with various attributes, as well as studies that observe existing 
relationships (Explorable.com, n.d.) as is the case with this study. This technique was 
chosen to evaluate the relationship between HAART regimen and development of high 
blood pressure, obesity, hyperglycemia because of the variableness of the characteristics 
of the target population. Each stratum was assigned the same sample size by the 
proportionate stratified random sampling where the same sampling fraction is allocated to 
each stratum (Explorable.com, n.d.). 
Sampling Frame and Sample Size  
I stratified my target population into four to accommodate all the categories of 
HIV-positive individuals assessing treatment in the clinic (Pre-ART, those who took 
HAART for six months, those who took HAART for twelve months, and those who 
received HAART for twelve months and above) from where I collected the samples. 
More so, eligible patients came for check-ups and refilled every three months, but did 
their blood tests every six months. The pre- HAART cases were infected individuals who 
were not eligible for antiretroviral therapy because their CD4+ cell count was above 350 
cells/mL thresholds for eligibility and served as the control group. Based on the 
assumptions that the outcome is binary and that there is a linear relationship between the 
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predictors and the log of the outcome variables (Field, 2009), power analysis to 
determine the sample size a priori was done.  
I used the G*Power 3.1.9.2 statistical power analysis software for the power 
analysis (Faul, Erdfelder, Buchner, & Lang, 2009). The power analysis was carried out to 
determine the sample size with the following parameters of the G* Power software: The 
Z test, logistic regression statistical test, binomial distribution, a power of 0.80, α of 0.05, 
and effect size as odds ratio of 2.333333 (Figure 1). I used the odds ratio because the 
outcome variable is binary (Karabi, 2012). I calculated the sample size to be 186, but the 
sample size was rounded to 192 (48 subjects per stratum). Samples were then allocated to 
the strata proportionately (Berhane et al., 2012). 
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Note. z tests - Logistic regression, tail(s) = two, odds ratio = 2.3333333 
 α = 0.05, power = 0.80, distribution = binomial, critical z = 1.9599640 
 total sample size = 186.  
 
 
 
 
 
 
 
 
 
 
Figure 1. G-power analysis required sample size a priori. 
61 
 
Inclusion and Exclusion Criteria  
 The population for the study included medical records of adult HIV patients 18 
years and older; those who adhered to taking HAART; those who had no abnormal blood 
glucose, BMI, and elevated blood pressure at baseline. I excluded the medical records of 
those below 18 years. The records of those who had elevated blood glucose, blood 
pressure, and abnormal BMI at baseline were also excluded from the study. Also 
excluded from the study were those whose records indicated pregnancy. 
Data Collection Instrument and Measurement of Patients’ Samples   
Information regarding age, sex, date of HAART initiation, type of HAART 
received, duration of HAART regimen, weight, height, blood pressure, CD4+ cell count, 
and fasting blood glucose were abstracted from the medical records of patients’ using an 
abstraction form  (Villamar et al., 2011). Blood pressure was measured using Reiseter 
Exacta sphygmomanometer (Rudolf Reiseter, Jungingen, Germany). Fasting blood 
glucose was measured using Selectra Junior chemistry auto analyser (ELITech Clinical 
Systems, Netherlands). Weight and height were measured using GT 131-120 health scale 
(Skyline Medical Equipment).  
Data Access and Collection Process  
 I sought permission and approval of the study from the Institutional Review 
Board (IRB) of Walden University following approval for data collection from medical 
records of patients by the Health Research Ethics Committee (HREC) of F.M.C. 
Umuahia. I removed every form of identifier that could link the patient to the study to 
62 
 
protect patients’ rights to confidentiality in agreement with the Helsinki Declaration 
(World Medical Association [WMA], 2008).  
Data Validity 
Data validity addresses the accuracy of the data (Creswell et al., 2009). According 
to Creswell et al., the manner of data collection (internal factors) can interfere with the 
validity of data. Data validity can be sectioned into internal and external validity (Cook & 
Campbell, 1979, p. 5.). Internal validity borders on the soundness of the design and 
analysis such as reliability of instrument and statistics, environment variables control, and 
characteristics of participants while external validity borders on the question of 
generalizability (Cook & Campbell, 1979, p. 5.). This includes the generalizability of the 
effect of the study to populations, measurement variables, treatment variables, and 
settings (Cook & Campbell, 1979, p. 5.). 
Since confidence in a study can be achieved with only valid data (Creswell et al., 
2009), I ensured data validity and reduced external threats to validity by determining 
whether data was stored electronically or by a paper chart. I also found out the type of 
information that was recorded as suggested by Hall, Schroder, and Weaver (2002). I also 
ensured data validity as stated by Engel, Henderson, Fergenbaum, and Colantonio (2009) 
by using trained data entry clerks in the medical records department of the ART clinic to 
abstract data from patients’ records. Furthermore, Engel et al. noted that the layout and 
content of the abstraction form could enhance the reliability of the data abstraction form. 
As a result, response fields on the abstraction form followed the order as it appeared in 
the records. To further enhance data validity, I coded the variables numerically and 
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aligned the response fields visually. I also justified to the right with no blank spaces to 
avoid transcription and data entry errors as suggested by Banks (1998).  
Statistical Power for Analysis   
 The margin of error also known as alpha (α) level or level of statistical 
significance is important when conducting epidemiologic studies and it is set a priori 
(Frankfort-Nachmias, & Nachmias, 2008). The alpha level is the level of error allowed to 
reject a true hypothesis (Frankfort-Nachmias, & Nachmias, 2008). Statistical significance 
is very vital in testing a statistical hypothesis. It plays a very crucial role in determining 
when to reject or accept a null hypothesis (Meier, Brudney, & Bohte, 2011). Thus, a p-
value of 0.05 (probability) is equivalent to a chance of 1 in 20 of rejecting a true 
hypothesis. By tradition, a p-value > .05 supports the null hypothesis and is not 
statistically significant. On the other hand, a p-value < .05 is considered statistically 
significant and does not support the null hypothesis (Frankfort-Nachmias, & Nachmias, 
2008). Based on this, the level of significance was set at 0.05. Furthermore, to have 
substantive and replicable results, the appropriate effect size must be applied as 
Frankfort-Nachmias, & Nachmias posited. According to Kelley & Preacher (2012), the 
quantitative measure of the strength of a phenomenon is the effect size. In addition, to 
prevent type II error with logistic regression, I set the power (1-β) at 80% with 95% 
Confidence interval (CI).  
Statistical Analysis   
Data that I extracted from the medical records were imputed manually into 
Microsoft Excel. I then exported the data into SPSS version 23 for analyses after 
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inspection and cleaning by excluding all missing data and used only records with 
complete data for the analysis as stated by Frankfort-Nachmias, and Nachmias (2008). I 
conducted descriptive statistics on my data and determined the prevalence of 
hypertension, obesity, and hyperglycemia using frequency distribution of demographic, 
laboratory, and clinical values. I also used the Chi-square test for independence (χ2) to 
determine the association between categorical variables according to the methods of 
Berhane et al. (2012). In addition, I used bivariate logistic analyses to identify predictors 
of hypertension, obesity, and hyperglycemia. Thereafter, I used the multivariate logistic 
regression analyses to analyse the independent variables that showed significant 
associations (p < .05) with the bivariate analyses. Furthermore, I used the multiple 
logistic regressions to estimate odds and odds ratio and controlled the effect of 
confounding variables. Multiple logistic regressions enabled me to examine the 
relationship between types of HAART regimen and high blood pressure, types of 
HAART regimen and obesity, and types of HAART regimen and hyperglycemia (Denue 
et al., 2012; Diouf et al., 2012). According to Kaneko et al. (2011); Wang et al. (2010), 
high blood pressure, obesity, and diabetes vary by characteristics of the population, and 
that gender, ethnicity, family history, differences in age, and smoking status contributes 
to differences in metabolic syndrome. These factors can alter the effects of HAART 
regimen on the dependent variables without being the direct cause of the outcome, 
thereby confounding the effect size of the dependent variables (Kaneko et al., 2011). 
Thus, preventing the effect of confounders informed the choice of multiple logistic 
regressions. Multiple logistic regressions allow controlling for confounding variables 
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(Szklo, & Nieto, 2014). According to Szklo and Nieto, multiple logistic regressions is 
used to examine relationships between the predictor variables, and the outcome 
(dependent) variable while allowing controlling for possible confounders. Multiple 
logistic regression is also used when the dependent or outcome variable is binary (Szklo, 
& Nieto, 2014). In this study, the outcome of interest is presence or absence of 
hypertension, presence or absence of obesity, and presence or absence of diabetes. The 
predictor variables (independent variables) are types of HAART regimen and duration of 
HAART regimen. However, using the directed acyclic graph (DAG), only age, and 
gender were included as covariates, CD4+ cell count was included as confounder. High 
blood pressure, obesity, and hyperglycemia were analyzed independently by creating 
dummy variables using the ATP III criteria (NCEP, 2002).  
In my data analysis, I included age and gender as covariates because they are 
patient variables, and they are related to the outcome variables only. However, I included 
CD4+ cell count that represents the immune status of the patient as a confounder because 
CD4+ cell count is related to both the exposure and the outcome (StraightHealthcare, 
2015). According to StraightHealthcare, covariates are patient variables that could be 
related or not related to the study outcome. But when the covariates are related to both 
the exposure and outcome, they become confounders.  
 Study Variables   
In this study, I derived the variables based on abstracted clinical information and 
laboratory test results from the medical records of HIV-infected individuals. I coded the 
outcome variables as presence of hypertension = 1, absence of hypertension = 0, presence 
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of obesity = 1, absence of obesity = 0, presence of hyperglycemia = 1, absence of 
hyperglycemia = 0. However, I coded the predictor variables (types of HAART regimen 
and duration of HAART regimen) at five and four levels respectively:  pre- HAART 
(control) = 0, the use of lamivudine, stavudine, nevirapine = 1; the use of combivir, 
nevirapine = 2; the use of combivir, efavirenz = 3; the use of truvada, efavirenz = 4; 
baseline = 0, HAART regimen for 6 months = 1, 12months = 2, >12 months = 3.  
Summary 
In this study, I analyzed data from medical records of HIV patients. The aims of 
this study are to: (a) examine the relationship among types of HAART regimen and 
hypertension, obesity, and hyperglycemia among adult HIV positive patients 18 years 
and older attending the clinic in F.M.C. Umuahia, Nigeria; (b) examine the relationship 
among duration of HAART regimen, hypertension, obesity, and hyperglycemia among 
adult HIV positive patients 18 years and older attending the clinic in F.M.C. Umuahia, 
Nigeria; (c) determine the prevalence of hypertension, obesity, and hyperglycemia among 
adult HIV positive patients 18 years and older attending the clinic in F.M.C. Umuahia, 
Nigeria. The study was limited to: (a) data available in patients’ medical records; (b) data 
that met the inclusion criteria of 18 years and older; (c) records that showed no evidence 
of abnormal blood glucose level, BMI, and hypertension at baseline.  
The effects of HAART on blood pressure, BMI, and blood sugar level were 
analyzed using logistic regression analysis. I based statistical significance on p < .05 and 
95% CIs. I took steps to ensure validity by minimizing bias, and also controlled 
confounders. Following approval of this study by the Walden University IRB and 
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approval to access patients’ medical records by HREC of F.M.C Umuahia, I then 
collected data, cleaned, coded, and analyzed data. Thereafter, I analyzed data statistically 
and present results in Chapter 4. 
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Chapter 4: Results 
 The purpose of this study was to analyse data from the treatment records of HIV-
positive individuals accessing treatment in the ART clinic in Federal Medical Centre 
(FMC), Umuahia quantitatively. In this study, I determined whether types of HAART 
regimen and duration of HAART regimen significantly affect the odds of hypertension, 
obesity, and hyperglycemia in HIV-positive individuals. The aim of this study was to 
answer two research questions: (a) what is the relationship among types of HAART 
regimen and hypertension, obesity, and hyperglycemia as metabolic syndrome 
components in HIV-infected individuals? ; (b) What is the relationship among duration of 
HAART regimen and hypertension, obesity, and hyperglycemia as metabolic syndrome 
components in HIV-infected individuals? I also sought to determine the prevalence of 
hypertension, obesity, and hyperglycemia among HIV-positive individuals receiving 
treatment at the ART clinic in FMC Umuahia in this study. 
In this chapter, I report the baseline descriptive and demographic characteristics 
of the sample population first. Then, I report the results of univariate analyses that 
justified the inclusion of covariates in the bivariate logistic model. Furthermore, I report 
the results of the multivariate logistic model after determining their individual effect on 
the outcome variables. In addition, I report the results of the multivariate logistic model 
after including age, gender, and CD4+ cell count to control their effect. I also summarize, 
tabulate, and report the findings of all statistical analysis about each hypothesis.  
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Data Access and Acquisition and Characteristics of Study Population  
Data Access and Acquisition 
I sought for and obtained approval to access patients' treatment records from the 
FMC HREC. The HREC approval number for the study is 
(FMC/QEH/G.596/Vol.10/166. Data collection and analysis for this study could start 
only when I got approval to carry out this study by Walden University’s IRB. The 
Walden University’s IRB approval number for the study is 04-08-16-0322042. I 
requested for Data from the medical records of all HIV-positive patients that accessed 
treatment in the ART clinic in FMC Umuahia between January 2009 and December 
2013. I then used only the records that met the inclusion criteria. I further derived 
variables as listed under study variables in Chapter 3.  
I coded all responses as described in Table 3 under study variables, and I limited 
the responses for the covariates to age and gender, and limited confounders to CD4+ T 
lymphocyte cell count. I limited the responses because other variables like family history 
of hypertension, family history of diabetes, alcohol use and cigarette smoking status of 
patients were not captured in the patients’ medical records. I also, used the term 
hyperglycemia instead of type 2 diabetes mellitus because there was no sufficient 
information such as Hb1C test, and information on the use of antidiabetic medication in 
the records of patients.  
Characteristics of Study Population 
In this retrospective study, I defined the sample size as the total number (n= 192) 
of treatment records of HIV-infected patients 18 years or older enrolled in the ART clinic 
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between January 2009 and December 2013 that met the inclusion criteria. Meanwhile, for 
the purpose of this study, I regarded the treatment records as participants, and I 
dichotomized continuous data for hypertension, obesity, and hyperglycemia using the 
ATP III criteria for hypertension and hyperglycemia and WHO criteria for obesity, as 
described in Chapter 3 (Tables 3 and 2, respectively). I also categorized age, CD4+ cell 
count, and WHO disease staging after obtaining their individual means. It is important to 
note that all the participants in the HAART group adhered to their regimen. Frequencies 
(number and percent) of the characteristics of the pre-HAART regimen control group and 
HAART regimen group collected from January 2009 to December 2013 are presented in 
Table 4. 
Table 4 shows the characteristics of the pre-HAART and HAART group. The 
sample size was 192 treatment records of HIV-positive patients 18 years and older. The 
sample was stratified into four groups, based on the duration of HAART regimen as 
follows: (a) pre-HAART (Control) = 48; (b) HAART group- 6months = 48; (c) HAART 
group -12 months = 48; (d) HAART group- >12 months = 48. In some comparison, I 
grouped three HAART groups as one single “HAART group” (Table 4). The pre-
HAART group consisted of only patients who were yet to commence the HAART 
regimen, whereas the HAART group consisted of HIV-positive patients on the HAART 
regimen. Of the 48 participants in the pre-HAART control group, 18 (12.5%) were males, 
whereas 30 (26.8%) were females. The age ranged between 18 years and 57 years. The 
mean value for age was 35.3years, with the majority of the participants in the 18-29 and 
40-50 years groups (Table 4). There was no participant on HAART regimen in the pre-
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HAART group. The immune statuses of patients as presented by CD4+ T lymphocyte 
cell count range was 201 cells/mL─> 500 cells/mL. The WHO HIV disease staging of all 
participants were below stage 3. Obesity was 12.5% prevalent with a mean BMI of 25.5. 
There was no observed presence of hypertension (0.0%) and hyperglycemia (0.0%) in the 
pre- HAART group (Table 4). Of the 144 participants in the HAART group, 59 (41.0%) 
were males whereas 85(59.0%) were females. The age ranged between 23 years and 65 
years, with a mean value of 38.7 years. The majority of the participants were in the age 
group 30-39 years (39.6%). In the HAART group, there were 82 (28.5%) participants on 
the lamivudine, stavudine and nevirapine regimen; 158 (54.9%) were on the combivir and 
nevirapine regimen, while 24 (8.3%) each were on the combivir and efavirenz, truvada 
and efavirenz regimen respectively. Obesity and hyperglycemia occurred in 16% and 
31% of the participants respectively. Systolic hypertension was 73.4 %, with a mean 
value of 142.2 mm Hg; diastolic hypertension was 26.6%, with a mean value of 93.4 mm 
Hg. The average value for BMI was 23.4 kg/m2, whereas the average value for fasting 
blood sugar was 85.9 mg/dL.  
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Table 4 
Characteristics of the Pre-HAART and HAART Group 
 
Variable Pre-HAART  
Frequency                        
N      (%)     
Mean value HAART group 
Frequency 
N      (%) 
Mean value  
Overall 
Gender 
48    (25%) - 144 (75%) - 
Male 18    (37.5) - 59     (41.0) - 
Female 30    (62.5) - 85     (59.0)   
Age group (years)     
18-29 15    (10.4) 35 21     (14.6) 38.7 
30-39 14     (9.7)  57     (39.6)  
40-50 15     (10.4)  54     (37.5)  
>50 0.4    (8.3)  12      (8.3)  
Type of HAART      
Lam,stav,nvp 0.0    (0.00) - 82      (28.5) - 
Comb,nvp 0.0    (0.00)  158    (54.9)  
Comb,efv 0.0    (0.00)  24      (8.3)  
Truv,efv 0.0    (0.00)  24      (8.3)  
CD4+ cell count 
(cells/mL) 
    
10-200 0.0    (0.00) 707 101    (35.1) 281 
201-350 0.0    (0.00)  113    (39.2)  
351-500  82     (56.9)  42      (14,6)  
>500 62     (43.1)  32      (11.1)  
WHO disease staging     
<3 48     (100) 1 253    (87.8) 1 
>2 0.0    (0.00)  35      (12.2)  
Hypertension(mm Hg)     
SBP (mm Hg) 0.0    (0.00) - 41      (73.4) 142.2 
DBP (mm Hg) 0.0    (0.00)  35      (26.6) 93.4 
BMI (Kg/m2)     
Obesity 18     (12.5) 25 16      (5.6) 23.4 
FBS (mg/dL)     
Hyperglycemia 0.0    (0.00) - 31      (10.8) 85.9 
Duration of HAART     
Baseline 0.0    (0.00) - 0        (0.00) - 
6 months 
12months   
>12 months                                                     
0.0    (0.00) 
0.0    (0.00) 
0.0 (0.00)
 48      (33.3) 
48      (33.3) 
48      (33.3) 
 
 
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria (NCEP, 2002). 
Obesity was defined according to WHO criteria (WHO, 2015). %= Percent, N=Number. Lam = 
Lamivudine, Stav = Stavudine, Nvp = Nevirapine, Comb = Combivir, Efv = Efavirenz, Truv = 
Truvada. SBP= Systolic blood pressure, DBP= Diastolic blood pressure. 
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Results 
Prevalence of Metabolic Syndrome Components 
To identify the prevalence of hypertension, obesity, and hyperglycemia, I 
excluded records of patients that showed baseline examination measurements within 
hypertensive, obesity, and hyperglycaemic range. Thereafter, I used descriptive statistics 
analysis to determine the prevalence of hypertension, obesity, and hyperglycemia. Total 
prevalence for the pre- HAART and HAART groups are presented in Table 5. Moreover, 
the prevalence of hypertension, obesity, and hyperglycemia stratified by gender and age 
in the HAART regimen group are presented in Table 6. I used the chi-square test (χ2) for 
independence to determine relationships between the duration of HAART regimen and 
hypertension, duration of HAART regimen and obesity, duration of HAART regimen and 
hyperglycemia using the 4 x 2 χ2 model.  
The crosstabs I conducted were between HAART regimen for 6 months, 12 
months, >12 months duration, and at baseline; and the presence or absence of each 
dependent variable (hypertension, obesity, and hyperglycemia). Results are presented in 
Table 7. The relationship between types of HAART regimen and metabolic syndrome 
components is shown in Table 8. The relationship between metabolic syndrome 
components and gender of patients on HAART is presented in Table 9, while the 
relationship between metabolic syndrome components and age is shown in Table 10. 
Odds ratios for hyperglycemia by type of HAART regimen is shown in Table 11. 
Relationships between the type of HAART regimen and the individual components were 
determined using χ2 and shown in Table 8. Statistically, significant associations were 
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determined by a p = < .05. Variables with statistically significant associations were 
further included in bivariate logistics regressions to determine the odds ratios (ORs) for 
the individual variables. Results of the ORs are presented in Tables 11 and 12 
respectively. After obtaining statistically significant ORs with each component, a final 
model was run with each component adjusted for all covariates to identify the adjusted 
effect of each independent variable on the dependent variables, while non-statistically 
significant variables were excluded from the final model. Results of final model are 
presented in Table 13. 
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Table 5 
Prevalence of Metabolic Syndrome Components in the Pre HAART and HAART Group 
 
                                                Pre-HAART                                         HAART 
Variable                          Value (N) Percent (%)                   Value (N)   Percent (%) 
 
Hypertension                           0.0                 0.0                               48              33.3  
 
Obesity                                   18.0               12.5                              16               5.6 
 
 
Hyperglycemia                        0.0                0.0                               31               10.8 
 
Note. Hypertension and hyperglycemia were defined by ATP III criteria (NCEP, 2002). 
Obesity was defined according to WHO criteria (WHO, 2015). 
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There was no prevalence (there were no cases) of hypertension and 
hyperglycemia in the pre-HAART control group (Table 5). However, in the HAART 
group, hypertension and hyperglycemia were 33.3% and 10.8% prevalent respectively 
(Table 5). The prevalence of obesity in the control group and HAART groups were 
12.5% and 5.6% respectively (Table 5). Obesity was 6.9% higher in the pre- HAART 
control group than the HAART group (5.6%) (Table5).  
In this study, the prevalence of hypertension in males (56.3%) is higher than in 
females (43.8%) (Table 6). Similarly, males were more likely to become obese (15.0%) 
than females (8.3%). Furthermore, hyperglycemia was 6% higher in males (25%) than in 
females (19%). Results also showed that prevalence of hypertension increase with age. In 
the 18─29 year age group, prevalence was 19.0% and in the 30─39 year group, 
prevalence was 19.3%. Prevalence rose to 29.6% in the 40-50 group and nearly doubled 
(58.3%) in the >50 year age group. Obesity prevalence was 8.8% in the 30-39 year age 
group, 16.7% in the 40─50 age groups, and 16.7% in the >50 age group. However, there 
was no obesity in the 18─29 age groups. Though hyperglycemia had a similar prevalence 
trend as obesity, there was 19.0% prevalence of hyperglycemia in the age group 18─29. 
Hyperglycemia prevalence was 17.5% in the age group 30-39; 27.8% in age group 40-5; 
and 16.7% in the >50 age group (Table 6). 
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Table 6  
Metabolic Syndrome Components Prevalence in Patients on HAART Regimen by Gender 
and Age 
 
Variable                          Gender                                  Age group (years)                                       
                                  Male       Female             18-29         30-39          40-50         >50    
                               %    (N )    %   (N )           %   (N )      %   (N )      %   (N )        %   N      
 
 Hypertension        56.3  (27)   43.8 (21)        19.0  (4)     19.3 (11)   29.6  (16)   58.3  (7)  
          
Obesity                 15.0    (9)     8.3   (7)         00.0  (0)      8.8   (5)    16.7  (9)     16.7   (2) 
                                  
Hyperglycemia    25.0   (15)    19.0  (16)      19.0  (4)     17.5 (10)     27.8 (15)   16.7   (2)        
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). %= 
Percent, N= Number 
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Tables 7 and 8 present the relationships between duration of HAART regimen and 
metabolic syndrome components and type of HAART regimen and metabolic syndrome 
components respectively. At baseline, there were no cases of hypertension (0.00%), 
obesity (0.00%), and hyperglycemia (0.00%). However, at six months, the prevalence of 
hypertension was 10.4%; obesity was 4.2%, and hyperglycemia was 6.3%. Furthermore, 
at 12 months on HAART regimen, the prevalence increased to 35.4% for hypertension, 
12.5% for obesity, and 18.8% for hyperglycemia. Similarly, the prevalence of 
hypertension and hyperglycemia were almost doubled with HAART regimen for >12 
months (54.2% and 39.6%), respectively. However, obesity was 16.7% prevalent at >12 
months (Table 7).  
The χ2 (20.813) for hypertension and its corresponding p < .001 (Table 7) showed 
that there was a statistically significant association between hypertension and duration of 
HAART regimen. The effect size (Cramer’s V = 0.380) for the association was large. The 
χ2 (24.353) and p < .001for obesity signified a statistically significant association 
between obesity and duration of HAART regimen. The effect size of 0.54 was large 
(Table 7). Similarly, χ2 for hyperglycemia was 63.08 and p < .001 also showed a 
statistically significant association between hyperglycemia and duration of HAART 
regimen. The effect size 0.468 was also large (Table 7).  
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Table 7 
Relationship Between Duration of HAART Regimen and Metabolic Syndrome 
Components 
 
Variable          Baseline    6months    12months    >12months   χ2       p-value      Effect  
                        %   (N )     %   (N )      %   (N )        %   (N )                                   size 
  
Hypertension   0.00 (0)   10.4  (5)    35.4 (17)      54.2 (26)    20.813   <0.001***  0.380 
  
 Obesity           0.00 (0)    4.2   (2)    12.5  (6)       16.7  (8)     24.354   <0.001***  0.291 
 
Hyperglycemia 0.00 (0)   6.3   (3)    18.8  (9)      39.6 (19)      60.91     <0.001*** 0.468 
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). %= 
Percent, N= Number, χ2= Chi-square test, *** = Significant 
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When stratified by types of HAART regimen, patients on the LAM, STAV, and 
NVR regimen, 8.5% patients were obese, 20.7% were hypertensive, and 15.9% had 
hyperglycemia. Also, with patients on the COMB, NVP regimen, 3.8% were obese, 9.5% 
hypertensive, and 6.3% of the patients had hyperglycemia. Similarly, 4.2%, 12.5%, 
12.5% of patients on the COMB, EFV regimen were obese, hypertensive, and had 
hyperglycemia respectively. Furthermore, with the TRUV, EFV regimen, there was 
obesity prevalence of 8.3%, hypertension was 12.5%, and hyperglycemia was 20.8% 
(Table 8). The χ2 and p-values for hypertension, obesity, and hyperglycemia were (χ2 = 
3.108, p = .375; χ2 = 2.761, p = .430; χ2 = 7.824, p = .045) respectively (Table 8).  
Results showed that there were no statistically significant associations between 
obesity and type of HAART regimen; hypertension and type of HAART regimen (p > 
.05). However, there was a statistically significant association between hyperglycemia 
and type of HAART regimen (p < .05) the association had a moderate effect size 0.167 
(Table 8). Types of HAART regimen was not included in the final regression models for 
hypertension and obesity because there was no statistically significant association 
between types of HAART regimen and hypertension, and types of HAART regimen and 
obesity. It is important to note here that where the assumption for Chi-square was 
violated, the likelihood ratio was used instead as was the case for hyperglycemia.  
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Table 8  
Relationship Between Types of HAART Regimen and Metabolic Syndrome Components 
 
Variable         Lam,stav,nvp      Comb,nvp    Comb,efv        Truv,efv       χ2        p- value    Effect  
                          %  (N )        %  (N )     % (N )         %  (N )                                 size                          
 
 Hypertension  15.9 (13)      6.3 (10)    12.5 (3)       20.8 (5)     3.108    0.375      Nil 
 
 Obesity            20.7(17)      9.5 (15)    12.5 (3)       12.5 (3)     2.761    0.430      Nil 
 
Hyperglycemia   8.5 (7)       3.8  (6)     4.2  (1)        8.3  (2)     7.824     0.045*   0.167     
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). %= 
Percent, N= Number, χ2= Chi-square test, * = Significant, Lam=Lamivudine, stav= 
Stavudine, nvp = Nevirapine, efv= Efavirenz, Truv= Truvada. 
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Research Questions 
The first research question was based on whether there is a relationship between 
types of HAART regimen and metabolic syndrome components. The second research 
question focused on whether there is a relationship between duration of HAART regimen 
and metabolic syndrome components. To answer these research questions one and two, I 
used the χ2 test to determine the associations between HAART regimen and metabolic 
syndrome components and duration of HAART regimen and metabolic syndrome 
components. I also used logistic regressions to identify bivariate odds ratio for 
hypertension, obesity, and hyperglycemia with and without each covariate and 
independent variable. This model was appropriate to determine the direction of the 
association with each of the dependent variable (hypertension, obesity, and 
hyperglycemia), and to determine if the independent variables were predictors of the 
outcome, and to know the odds of developing hypertension, obesity, and hyperglycemia. 
In addition, I used multiple logistics regression that included all covariates, but excluded 
non-significant variables as the final model. Results of the final regression model are 
presented in Table 13. All continuous variables were categorized. Results of the χ2 tests 
are shown in Tables 7 and 8. The relationship between metabolic syndrome components 
and gender of patients on HAART is presented in Table 9, while the relationship between 
metabolic syndrome components and age of patients on HAART is shown in Table 10. 
The bivariate logistic regression analyses are presented in Tables 11 and 12.  
Results of the χ2 test showed that there was no statistically significant association 
between types of HAART regimen and hypertension (χ2 = 3.108, p = .375 > .05, Table 
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8). As a result, types of HAART regimen were excluded from the bivariate logistics 
regression to determine odds of hypertension. Types of HAART regimen were also 
excluded from the bivariate logistics regression to determine odds of obesity because 
there was no significant association between types of HAART regimen and obesity (χ2 = 
2.761, p = .430) (Table 8). 
The relationship between metabolic syndrome components and gender of patients 
on HAART is presented in Table 9. The Chi-square test for hypertension was 57.600 and 
its corresponding p < .001. The χ2 showed that gender is statistically significantly related 
to hypertension. The effect size for the association was large (0.447). Chi-square for 
obesity was 16.941, p = .002, < .05. This indicated that gender was statistically 
significantly related to obesity. The association also had a medium effect size (0.243). 
Similarly, χ2 for hyperglycemia was 34.739, p-value < .001. This χ2 result implied that 
gender is statistically significantly related to hyperglycemia. The effect size was 0.347 
(Table 9). Results justified the inclusion of gender as a covariate in the final model.  
The relationship between metabolic syndrome components and age of patients on 
HAART is presented in Table 10. The χ2 test for hypertension was 55.122 and its 
corresponding p < .001. This showed that age is statistically significantly related to 
hypertension. The effect size for the association was large (0.425). Chi-square for obesity 
was 21.510, p = 0.03, < .05 indicated that age was statistically significantly related to 
obesity. The association had a medium effect size (0.221). Similarly, χ2 for 
hyperglycemia was 33.740, p = < .001. This χ2 result implied that age is statistically 
84 
 
significantly related to hyperglycemia. The effect size was 0.351 (Table 10). Results 
justified the inclusion of age as a covariate in the final model. 
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Table 9 
Relationship Between Metabolic Syndrome Components and Gender of Patients on 
HAART 
 
Variable                Chi-square (χ2)/         p-value          Effect size            Significance 
                               Likelihood ratio                                                         
  
 
Hypertension                 57.600                < .001              0.447                        S 
 
Obesity                          16.941                   .002              0.243                        S 
 
Hyperglycemia              34.739                 < .001              0.347                       S 
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S= 
Significant, 
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Table 10 
Relationship Between Metabolic Syndrome Components and Age of Patients on HAART 
 
Variable                      Chi-square (χ2)/          p-value        Effect size       Significance 
                                     Likelihood ratio                                                         
  
Hypertension                55.122                        < .001             0.425                      S 
 
Obesity                         21.510                         < .03              0.221                      S 
 
Hyperglycemia             33.740                        < .001             0.351                      S 
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S= 
Significant. 
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ORs of hyperglycemia with the COMB and NVR; COMB and EFV; TRUV and 
EFV regimen were 1.14 (95% CI, 0.526, 2.463); 3.11 (95% CI, 1.393, 6.944) and 1.13 
(95% CI, 0.257, 5.00) respectively (Table 11). These ORs indicated that patients on 
COMB and NVR regimen are 1.14 times odds of hyperglycemia, those on COMB and 
EFV are 3.11 times odds of hyperglycemia, and those on TRUV and EFV 1.13 times 
odds of having hyperglycemia, compared with patients on LAM, STAV, NVP (reference 
group). Results showed that COMB and EFV regimen was statistically significantly 
related to hyperglycemia (p = 0.006 < .05) (Table 11). However, I found COMB/ NVR 
regimen and TRUV/ EFV regimen statistically not significantly related to hyperglycemia 
(p = 0.742 and p = 0.867), respectively p > .05. Also, I could not predict the relationship 
between LAM, STAV, NVP regimen and the dependent variables using the model.  
The OR for hypertension at 12 months duration of HAART regimen was 3.10 
(95% CI, 1.299, 7.352). This OR showed that patients are 3.10 times odds of developing 
hypertension when on HAART regimen for 12 months. Odds ratio of 9.62 (95% CI, 
3.205, 28.57) at >12 months indicated that patients on HAART for more than 12 months 
are 9.62 times odds of developing hypertension. Results also showed that duration of 
HAART was statistically significantly related to hypertension (p = .011< .05). 
Furthermore, after controlling for the covariates, there were increases in the unadjusted 
ORs for hypertension from 3.1(95% CI, 1.299, 7.352) (Table 12) to AOR = 4.15(95% CI, 
1.949, 8.849) at 12 months and from OR 9.6 (95% CI, 3.205, 28.57) to AOR = 18.52 (CI, 
5.464, 42.50) at >12 months (Table 13). Duration of HAART was still statistically 
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significantly related to hypertension p < .001). The R2 was 0.498, signifying that 49.8% 
of the variance could be explained.  
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Table 11 
Odds Ratio (OR) for Hyperglycemia by Types of HAART Regimen 
 
Variable                  Types of              OR(95% CI)              p- value        Sig           R2        
                                HAART                        
  
Hyperglycemia  
                                 Lam,stav,nvp          referent                          -                 -         0.816 
 
                              Comb,nvp              1.14 (0.526, 2.463)      0.742          NS       
 
                                 Comb,efv               3.11 (1.393,  6.944)     0.006           S 
 
                              Truv,efv                 1.13 (0.257, 5.000)      0.867          NS              
                              
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S= 
Significant, NS= Not significant. OR=Odds ratio, CI= Confidence interval, 
Sig=Significance, Lam=Lamivudine, stav= Stavudine, nvp = Nevirapine, efv= Efavirenz, 
Truv= Truvada. 
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Table 12 
Odds Ratio (OR) for Metabolic Syndrome Components by Duration of HAART Regimen  
 
 
Variable       Duration on             OR         95% CI           p- value       Sig           R2                     
                    HAART (months)   
 Hypertension   
                            Baseline           -                     -                       -             -         0.498                                                    
                               6                referent              -                       -             - 
                              12                 3.1         1.299, 7.352            0.011        S                       
                            >12                 9.6         3.205, 28.57            0.001        S 
Obesity              
                           Baseline             -                     -                       -             -         0.868 
                               6                referent               -                       -            - 
                              12                 1.71       0.590, 4.950            0.322       NS 
                            >12                 5.95       1.284, 18.770          0.023        S       
Hyperglycemia  
                           Baseline              -                     -                        -           -        0.816                                                                                                                        
                               6                   referent             -                       -           -       
                              12                  2.23       0.910, 5.681           0.079       NS              
                            >12                  8.33      2.283, 30.303          0.001        S   
                     
 
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S= 
Significant, NS= Not significant. OR=Odds ratio, CI= Confidence interval, 
Sig=Significance 
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ORs and corresponding confidence interval (CI) for obesity at 12 months and >12 
months were 1.71(95% CI, 0.590, 4.950) and 5.95 (95% CI, 1.284, 27.77) respectively 
(Table 12). These ORs show that obesity is 5.95 times more likely to develop when on 
HAART for >12 months and 1.71 times more likely to develop when on HAART for 12 
months. However, after controlling for gender, age, and CD4+ cell count, the OR for 
obesity increased to AOR= 1.82 when on HAART for 12 months and increased to AOR 
5.44 when on HAART for >12 months (Table 13). Statistically, HAART regimen for >12 
months was significantly related to obesity (p = .023 < .05), whereas, HAART regimen 
for 12 months only was statistically not significantly related to obesity (p = 0.322 > .05) 
(Table 12). However, after adjustment for covariates, it resulted in statistical significance 
at 12 months duration (p < .001). R2 was 0.868, showing that 86.8% of the variance could 
be explained.  
Hyperglycemia was 2.23 times odds of developing in patients on HAART for12 
months (OR= 2.23, 95% CI, 0.910, 5.681) (Table 12) and 8.33 times odds of developing 
in patients on HAART for >12 months (OR= 8.33, 95% CI, 2.283, 30.303) (Table 12). 
However, after controlling for all the covariates, OR was nearly doubled (AOR= 3.91) 
when on HAART for 12 months. Similarly, OR was nearly doubled (AOR= 14.71) when 
on HAART for >12 months (Table 13). There was no prediction at baseline and 6 
months. The results showed that gender, age, and CD4+ cell count have an influence on 
the dependent variables. R2 of 0.816 showed that 81.6% of the variance could be 
explained. Statistically, unadjusted OR of the group on HAART for 12 months was not 
significant (p = .079), while the group on HAART for >12 months was statistically 
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significantly related to hyperglycemia (p = .001 < .05). Furthermore, after adjusting for 
covariates, statistical significance was achieved for both groups. Consequently, I rejected 
the null hypothesis and accepted the alternative hypothesis that duration of HAART 
regimen increases the odds of hyperglycemia.  
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Table 13 
Adjusted Odds Ratio for Metabolic Syndrome Components by Duration of HAART 
Regimen 
 
Variable         Duration               AOR (95% CI)             p- value         Sig           R2 
                       on   HAART                        
Hypertension       
                             Baseline           -                    -                       -             -         0.793                                                                                               
                               6               referent               -                       -             -       
                              12                4.15       1.949, 8.849          < .001         S 
                            >12               18.52      5.464, 42.50          < .001         S                           
Obesity              
                           Baseline            -                   -                           -            -         0.835 
                               6               referent             -                           -            -       
                             12                1.82        4.349, 26.92           < .001        S       
                           >12                5.43       2.227, 13.158          < .001        S    
Hyperglycemia  
                           Baseline           -                     -                            -          -        0.800                    
                             6                referent               -                            -          -       
                            12                  3.91        1.942, 9.259            < .001      S        
                          >12                14.71       4.425, 27.619           < .001      S 
                            
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S = 
Significant, NS = Not significant. AOR= Adjusted odds ratio, CI= Confidence interval, 
Sig = Significance. 
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The relationship between immune statuses of patients measured by CD4+ T 
lymphocyte and metabolic syndrome components is presented in Table 14. The χ2 test for 
hypertension was 45.140 and its corresponding p < .001. This showed that CD4+ cell 
count was statistically significantly related to hypertension. The effect size for the 
association was large (0.396). Chi-square for obesity was 19.780, p-value = .003 < .05 
indicated that CD4+ cell count was statistically significantly related to obesity. The 
association also had a medium effect size (0.262). Similarly, χ2 for hyperglycemia was 
27.327, p-value < .001. This χ2 result implies that CD4+ cell count is statistically 
significantly related to hyperglycemia. The effect size was 0.308 (Table 14). The results 
justified the inclusion of CD4+ T-lymphocyte count as a covariate in the final model. 
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Table 14 
Relationship Between Metabolic Syndrome Components and Immune Status of Patients 
on HAART 
 
Variable                  Chi-square (χ2)/         p-value           Effect size           Significance 
                                Likelihood ratio                                                         
  
Hypertension                 45.140                   < .001                 0.396                          S 
 
Obesity                          19.780                      .003                 0.262                          S 
 
Hyperglycemia              27.327                   < .001                 0.308                          S 
 
 
Note. Hypertension and hyperglycemia were defined according to ATP III criteria 
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S = 
Significant, NS = Not significant.  
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Summary 
The characteristics of the population studied include gender, age, WHO HIV 
disease staging, CD4+ T lymphocyte cell count, blood pressure measurement, body mass 
index, and fasting blood sugar level in the pre-HAART control group and HAART group. 
The variables were assessed at baseline and thereafter as recorded in their treatment 
records. All the participants in the HAART group adhered to their regimen. Most of the 
participants in the HAART group were in WHO disease stage < 3 at enrolment and a few 
in WHO stages 3. Unlike the HAART group, all the participants in the pre-HAART 
group at enrolment were in WHO disease stage 1. There were 59 males and 85 females in 
the HAART group, whereas the pre-HAART group had 18 males and 30 females. The 
mean value for age in the pre-HAART group was 35.25 years, and that of the HAART 
group was 38.7 years. The average values for CD4+ cell count in the pre-HAART group 
and HAART group were 707cells/mL and 281.6cells/mL respectively. I stratified the 
HAART group into three according to the duration of HAART regimen. Each stratum 
had 48 participants each at six months, 12 months, and >12 months. The HAART group 
also had 82 participants on the Lamivudine, Stavudine, and Nevirapine regimen, 158 on 
the Combivir and Nevirapine regimen, 24 participants each on Combivir and Efavirenz 
regimen and Truvada and Efavirenz regimen. 
In the determination of the prevalence of the metabolic syndrome components, I 
found that 18 (12.5%) participants in the pre-HAART group were obese at baseline. 
However, there were no cases of hypertension and hyperglycemia at baseline. The 
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prevalence of systolic and diastolic hypertension was 73.4% and 26.6% respectively, and 
the overall prevalence of hypertension was 16.7%.  
I stratified the independent variables by types of HAART regimen and duration of 
HAART regimen. I used the χ2 test for independence to examine the relationships 
between the nonparametric variables. I also analyzed the bivariate odds of covariates 
(age, gender, and CD4+ cell count); I then included only statistically significant variables 
in the final model. The results showed that ORs differed by duration of HAART for all 
components, but differed less for the types of HAART regimen. To control for the 
potential influence of covariates on metabolic syndrome components, I included 
covariates to the multiple logistic regression models that served as the final model. I used 
multiple logistic regression analysis to assess odds ratios of types of HAART regimen 
and duration of HAART regimen after controlling for all covariates. This was done to 
determine whether these variables increased the odds of hypertension, obesity, and 
hyperglycemia. 
In this study, the odds of hypertension, obesity, and hyperglycemia increased with 
duration of HAART, and I recorded statistical significance with hypertension in the 
group on HAART for 12 months and the group on HAART for >12 months (p < .05). I 
also recorded statistical significance with obesity and hyperglycemia in the group on 
HAART for >12 months only (p < .05). However, there was no statistical significance 
with obesity and hyperglycemia in the group on HAART for 12 months (p > .05). The 
OR for hypertension at 12 months was 3.1 (95% CI, 1.299, 7.352, p < .05), at >12 months 
OR was 9.6 (95% CI, 3.205, 28.57, p < .05). The OR for obesity at 12 months was 1.71 
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(95% CI, 0.590, 4.950, p > .05), at >12 months OR was 5.95 (95% CI, 1.284, 18.770). 
The OR for hyperglycemia at 12 months was 2.23 (95% CI, 0.910, 5.681, p > .05), at >12 
months OR was 8.33 (95% CI, 2.283, 30.303, p < .05). Conversely, types of HAART 
regimen did not increase odds of hyperglycemia. The OR for hyperglycemia with the 
COMB, NVP regimen was 1.14 (95% CI, 0.526, 2.463), with the COMB, EFV regimen 
OR was 3.11 (95% CI, 1.393, 6.944, p = .006), with the TRUV, EFV regimen OR was 
1.13 (CI, 0.257, 5.000, p = .867). OR with HAART regimen was not done for 
hypertension and obesity because of the no significant association results obtained with 
the χ2 test.  
The odds of hyperglycemia did not increase with the Combivir and Nevirapine 
regimen (OR=1.14, 95% CI, 0.526, 2.463, p > .05) and the Truvada and Efavirenz 
regimen (OR=1.13, 95% CI, 0.257, 5.000, p = .867). Only the Combivir and Efavirenz 
regimen (OR=3.11, 95% CI, 1.393, 6.944, p = .006) achieved statistical significance and 
increased the odds of hypertension, obesity, and hyperglycemia. 
I accepted the null hypothesis (H0) for research question 1A that stated that 
HAART regimen does not increase the odds of hypertension and rejected the alternative 
hypothesis because of lack of statistical significance. Similarly, due to no statistically 
significant relationship between types of HAART regimen and obesity, I accepted the 
null hypothesis for research question 1B that stated that HAART regimen does not 
increase the odds of obesity and rejected the alternative hypothesis. Furthermore, due to 
no statistically significant relationship, I accepted the null hypothesis for research 
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question 1C that stated that types of HAART regimen does not increase the odds of 
hyperglycemia and rejected the alternative hypothesis.  
For research question 2A, the results generated produced statistically significant 
relationship to reject the null hypothesis in favor of the alternative hypothesis that stated 
that duration of HAART regimen increases the odds of hypertension (AOR = 4.15, 95% 
CI, 1.949, 8.849, p < .001) with the group on HAART for 12 months and AOR = 18.52 
(95% CI, 5.464, 42.50) with the group on HAART for >12 months. I also rejected the 
null hypothesis for research question 2B and accepted the alternative hypothesis that 
stated that duration of HAART regimen increases the odds of obesity with respect to 
duration of HAART for 12 months AOR=1.82 (95% CI, 4.349, 26.92, p < .001) and 
HAART for >12 months (AOR= 5.43 (CI, 2.227, 13.158, p < .001). Furthermore, for 
research question 2C, I accepted the alternative hypothesis that stated that duration of 
HAART increases the odds of hyperglycemia and rejected the null because the result was 
statistically significant (AOR =3.91, 95% CI, 1.942, 9.259, p < .001) at 12 months and 
AOR = 14.71 (95% CI, 4.425, 27.619, p < .001) at >12 months. 
In chapter 5, I interpret and discuss the results presented in this chapter. I 
interpreted the results based on the metabolic theory and literature reviewed. I also 
discuss the strengths and limitations of this study in Chapter 5. In addition, I present the 
importance of the findings of this study to the population and recommend further in-
depth studies with primary data to validate the results of this study. I also discuss 
recommendations for possible future intervention programs in chapter 5. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Discussion 
The purpose of this study was to quantitatively analyze data from the treatment 
records of HIV-positive individuals accessing treatment in the ART clinic in FMC, 
Umuahia. I also determined whether HAART regimen and duration of HAART regimen 
increased the odds of developing hypertension, obesity, and hyperglycemia in HIV-
positive individuals. The aim of this study was to answer two research questions: (a) what 
is the relationship among types of HAART regimen and hypertension, obesity, and 
hyperglycemia as metabolic syndrome components in HIV-infected individuals?; (b) 
what is the relationship among duration of HAART regimen and hypertension, obesity, 
hyperglycemia as metabolic syndrome components in HIV-infected individuals? In 
addition, I determined the prevalence of hypertension, obesity, and hyperglycemia among 
HIV-positive individuals 18 years or older receiving treatment in the ART clinic in FMC 
Umuahia. 
In this study, I found a significantly high burden of hypertension (33.3%) and 
hyperglycemia (10.8%) of the diabetic range among HIV-positive patients accessing 
treatment in the ART clinic in FMC Umuahia. But obesity prevalence (5.6%) was not as 
high. Hypertension, obesity, and hyperglycemia constitute major risk factors for CVD in 
these groups of population (Chow et al., 2012; Guaraldi, et al., 2010; Palios, Kadoglou, 
and Lampropoulos, 2012; Malangu, 2014; Muhammad et al., 2013; Zhou et al., 2014). 
These risk factors, however, vary by population and racial differences (Ngatchou et al., 
2013).  
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Metabolic syndrome components prevalence in HIV-infected individuals 
associated with HAART regimen has been observed in cross-sectional observational 
studies (Durang et al., 2011; Guaraldi, et al., 2010; Palios, Kadoglou, and Lampropoulos, 
2012; Ngatchou et al., 2013). Before my study, there had been no report on the analysis 
of the relationship between HAART regimen and metabolic syndrome components in 
Umuahia metropolis. In this chapter, I interpret and discuss the findings presented in 
Chapter 4. I also discuss the study limitations, the strength of the study, and 
recommendations for further study based on the findings of this study. I also discuss the 
implications for positive social change and public health practice, and the summary of the 
key results of this study. 
Interpretation of Findings 
In this study, I used data from HIV- positive patients accessing treatment in FMC 
Umuahia to provide information about the relationship among types of HAART regimen 
and hypertension, obesity, and hyperglycemia; and the relationship among the duration of 
HAART regimen and hypertension, obesity, and hyperglycemia. Information on the 
prevalence of hypertension, obesity, and hyperglycemia among HIV-positive patients 18 
years and older that were managed for HIV infection was also provided. The results of 
this study showed that duration of HAART regimen is strongly related to hypertension 
and hyperglycemia; less so with obesity and that hypertension tends to develop in 
patients on HAART regimen for more than 12 months (OR = 9.6). Key findings of this 
study confirmed suspicions that duration of HAART regimen increased the odds of 
developing hypertension and hyperglycemia in HIV patients, and that the factors 
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associated with statistical significance were taking HAART regimen for more than 12 
months. 
Prevalence of Metabolic Syndrome Components 
Hypertension and diabetes were defined according to the ATP III criteria (NCEP, 
2002), while obesity was defined according to WHO criteria (WHO, 2015). The overall 
prevalence of hypertension was 33.3%; that of hyperglycemia was 10.5%, and only 5.6% 
obesity prevalence was recorded in this study. The results of this study are consistent 
with previous prevalence reports on metabolic syndrome components (Berhane et al., 
2012; Denue et al., 2012; Dimodi et al., 2014). Similar to my study results, are the results 
obtained by Gazzaruso et al. (2003) was 34.2% hypertension in patients on HAART.  
Though the overall study population was relatively young (average age was 34.5 
years in the pre-HAART group and 38.7 years average age in the HAART group), 
hypertension, obesity, and hyperglycemia were more prevalent in the older age groups 
than in the younger age groups. This result is consistent with the results of Muhammad et 
al. (2013) who reported a mean age of 32.5 years in their study.  
Metabolic syndrome components were more prevalent in males than in females in 
this study, and prevalence also increased with age. This result is consistent with the 
reports of Malangu (2014) that male patients were 2-fold more likely to have metabolic 
syndrome compared to females.  
Muhammad et al. (2013) evaluated the cardiovascular risks among patients on 
HAART in a cross-sectional study amongst HIV patients placed on HAART for at least 
six months, and HAART- naïve group in Aminu Kano Teaching Hospital, Nigeria. They 
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compared the prevalence of metabolic syndrome components in the pre- HAART group 
and the HAART group. Their result showed that the incidence of hypertension in patients 
exposed to HAART regimen was approximately eight times higher than the non-exposed, 
17% and 2% respectively (p < .001). Obesity prevalence of 2% and 11% was recorded in 
the HAART naïve and HAART groups respectively and diabetes prevalence of 3% in 
each of the two groups.  
The study established significant correlations in cardiovascular risk factors such 
as hypertension, obesity, diabetes, and hypercholesterolemia in patients treated with 
HAART. But their results are not totally consistent with the results of this study. In my 
study, I found higher obesity prevalence in the pre- HAART group (12.5%). However, 
results obtained in this study are consistent to that obtained in the Data Collection on 
Adverse Events of Anti-HIV Drugs (D. A. D) study where HAART naïve subjects were 
more obese than the subjects on HAART. Akinboro, Onayemi, Ayodele, Mejiuni, and 
Atiba (2013) also reported the presence of obesity 33.97±1.06 in the pre-HAART group 
and no obesity in the HAART group. The recorded higher obesity prevalence in the pre- 
HAART group may have stemmed from the fact that patients in the pre- HAART group 
had higher mean CD4+ cell count (707cells/ml), and were all at WHO HIV disease stage 
1. At this stage, weight loss and other opportunistic infections had not set in compared to 
the HAART group with mean CD4+ value of 281cells/ml. In contrast, our study did not 
observe any hypertension and hyperglycemia prevalence in the pre- HAART group. 
However, there was no statistically significant association between HAART regimen and 
hypertension (χ2= 3.108, p = 0.375). Denue et al. (2012) and Muhammed et al. (2013) in 
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their studies also reported a non-statistically significant relationship between HAART 
and hypertension (p > 0.05).  
All participants in the HAART group were on the 2NRTI plus 1 NNRTI regimen. 
The regimens were in a cocktail of four different combinations as follows: (a) 
Lamivudine, Stavudine, and Nevirapine (b) Combivir and Nevirapine (c) Combivir and 
Efavirenz (d) Truvada and Efavirenz. None of the patients were on a PI containing 
regimen. The pre- HAART control group had no patient on HAART. The development of 
metabolic syndrome component is likely to be as a result of the exposure to HAART. But 
the relationship that exist between the individual antiretroviral agent and metabolic 
syndrome components is not clear.  
In this study, the prevalence of hypertension was higher in patients on the 
Truvada and Efavirenz regimen (20.8%), while obesity and hyperglycemia were observed 
more in patients on the Lamivudine, Stavudine, and Nevirapine regimen (20.7%) and 
(8.5%) respectively. However, there was no statistically significant association (p > .05) 
between types of HAART regimen and metabolic syndrome components. This finding of 
a non-statistically significant relationship between types of HAART regimen and 
metabolic syndrome components is similar to the previous findings of Denue et al. 
(2012). They found no statistical significance between classes of HAART and 
hypertension.  
In this study, the prevalence of the three metabolic syndrome components 
increased with duration of HAART regimen. This result agrees with the report of 
Berhane et al. (2012), where they found the duration of HAART to be independently 
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associated with metabolic syndrome components. In their study, they found factors 
associated with metabolic syndrome to be taking HAART for over twelve months. 
Similarly, the effect of duration of HAART regimen was also reported by Malangu 
(2014). Malangu indicated that prevalence of metabolic syndrome components was 
higher as the length of treatment increased. This suggests that the use of HAART for 
more than 12 months predisposes patients to develop metabolic syndrome. 
Relationship Among Types of HAART Regimen, Duration of HAART Regimen and 
Hypertension  
Based on the total medical records of HIV-positive patients 18 years or older that 
met the eligibility criteria, more than 30% of patients were hypertensive by ATP III 
criteria that specified hypertension as systolic blood pressure measurement ≥130 and a 
diastolic blood pressure measurement  ≥85mm Hg (NCEP, 2002). The ≥130/85 mm Hg 
range implies an increasing blood pressure that can reach the categorical level for 
hypertension since hypertension is a progressive condition. The 33.3% recorded in this 
study was higher than the 15.9% reported by Sachithananthan et al. (2012) in Ethiopia. 
Prevalence was higher among males (56.3%) and the group older than 50 years (58.3%). 
This result is consistent with previous research results by Malangu (2014) and Denue et 
al. (2012). To determine if the relationship between HAART regimen and hypertension 
and the relationship between duration of HAART regimen and hypertension are 
statistically significant, I used the χ2 test of independence. The χ2 for types of HAART 
regimen and hypertension (3.108, p = 0.375) suggested that there was no association 
between HAART regimen and hypertension. Muhammed et al. (2013) reported similar 
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findings in a previous study that HAART was not statistically significantly associated 
with hypertension. However, χ2 (20.813, p < .001) for duration of HAART and 
hypertension showed that there is an association. The effect size (0.380) signifies a large 
effect size. Further bivariate logistic regression analysis revealed that hypertension was 
more than 3 times (OR= 3.10, 95% CI, 1.299, 7.352) likely to develop in patients on 
HAART for 12 months, and more than 9 times (OR 9.62, 95% CI, 3.205, 28.57) as likely 
for patients on HAART for more than 12 months, compared with patients on HAART 
regimen for less than 12 months.  
Despite the increase in ORs by more than one fold and more than 8-fold  after 
controlling for covariates, statistical significance for hypertension was still maintained for 
the duration of HAART for 12 months and >12 months respectively. As a result, the null 
hypothesis that duration of HAART does not increase the odds of hypertension was 
rejected. Denue et al. (2012) reported similar results. Their study examined the impact of 
HAART on blood pressure after two years of commencement of HAART in a cohort of 
227 HIV patients. Their results showed a rise in blood pressure with time. The study by 
Arruda Junior et al. (2010) also is consistent with our results. Furthermore, this study 
demonstrated that the significant increase in OR for hypertension when all covariates 
were controlled, indicated that the actual independent effect of duration of HAART on 
hypertension was not confounded by age, gender, and CD4+ cell count.  
Relationship Among HAART regimen, Duration of HAART Regimen and Obesity 
Using the WHO definition of obesity, I considered BMI ≥30 kg/m2 obese, and 
regarded BMI ≤ 30 kg/m2 as not obese. The literature reviewed showed that exposure to 
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HAART affects body fat distribution in HIV-infected patients and also increases the risk 
of CVD (Brown et al., 2009). Based on the above definition of obesity, this study showed 
overall obesity of 5.6% and χ2 for HAART regimen and obesity was 2.761, p = .430. This 
result implies that the association between obesity and HAART regimen is not 
statistically significant.  
Due to the inability to observe a significant association between HAART regimen 
and obesity, HAART regimen was excluded from the subsequent logistics regression 
models. As a result of the insufficient evidence to accept the alternative hypothesis, the 
null hypothesis that HAART regimen does not increase the odds of obesity was accepted. 
Muhammed et al. (2013) reported similar findings of no association between obesity and 
HAART regimen. While this study was unable to establish that HAART regimen 
statistically significantly increased odds of obesity, several other studies did observe 
statistical significance (Dimodi et al., 2014; Jacobson, Tang, Spiegelman, Thomas, 
Skinner, Gorbach, et al., 2006; and Wu et al., 2012). Conversely, there was a statistically 
significant association between obesity and duration of HAART (χ2 = 24.354, p < .001).  
Further bivariate logistic regressions analysis produced results that supported the 
association between duration of HAART and obesity. ORs indicated that obesity is nearly 
2 folds (OR= 1.71, 95% CI= 0.590, 4.950) more likely in patients on HAART regimen 
for 12 and more than 5 folds (OR= 5.95, 95% CI= 1.284, 27.77) more likely in patients 
on HAART regimen for >12 months, respectively. This result is consistent with the 
findings of Sharma et al. (2014) where they reported statistical significance p < .05 
between duration of HAART and obesity. However, adjusting for covariates increased 
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the ORs by more than a fold for patients on HAART for 12 months (AOR= 4.15, 95% 
CI, 1.949, 8.849), and increased the OR by more than 8 fold for patients on HAART for 
>12 months (AOR = 18.52, 95% CI, 5.464, 42.50) on HAART, respectively.  
Relationship Among HAART Regimen, Duration of HAART Regimen and 
Hyperglycemia 
Diabetes was defined according to the ATP III definition of fasting blood glucose 
>100mg/dl (NCEP, 2002). However, due to the absence of other diabetes mellitus indices 
such as Hb A1C test results in patients’ records, I chose to use the term hyperglycemia 
instead. Like hypertension, type 2 diabetes mellitus is a progressive condition. Elevated 
blood glucose (hyperglycemia) is a marker for insulin resistance, which together with 
glucose intolerance lead to chronically high circulating blood sugars which subsequently 
results in diabetes mellitus (Reaven, 1988; Schneider, 2014). Based on the definition, 
overall hyperglycemia in this study was 10.5%. This result is similar to the 8% reported 
by Sachithananthan et al. (2012) in Ethiopia. In examining the relationship between 
HAART and hyperglycemia and the relationship between duration of HAART and 
hyperglycemia, χ2 = 0.167, p = .045 and χ2 = 63.08, p < .001 were obtained for HAART 
regimen and duration of HAART regimen, respectively. These associations were 
statistically significant with medium (0.167 for HAART) to large (0.468 for the duration 
on HAART) effect size, respectively.  
Further bivariate logistic regressions showed odds of hyperglycemia was more 
than two folds at 12 months (OR= 2.23, 95% CI= 0.910, 5.681) and more than 8-fold at 
>12 months (OR= 8.33, 95% CI= 2.283, 30.303). There was no statistical significance at 
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12 months before adjustment. However, adjusting for covariates increased OR by nearly 
2-fold (AOR= 4.15) and statistical significance at 12 months (p < .001). Also, after taking 
age, gender, and CD4+ cell count into account in subsequent analyses to control for their 
influence,  HAART regimen at >12 months OR dropped by more than 6-fold (AOR= 
1.82), but maintained statistical significance (p < .001). Thus, there was sufficient 
evidence to reject the null hypothesis and accept the alternative hypothesis that duration 
of HAART regimen increases the odds of hyperglycemia. Abebe et al. (2014) reported a 
similar result in their study conducted in Ethiopia, where they examined the association 
between antiretroviral treatment and hyperglycemia and dyslipidemia. Diouf et al. (2012) 
in Senegal also reported associations between prolonged exposure to HAART and 
diabetes. However, Hansen et al. (2009) had a different report of no association between 
presence of metabolic syndrome and HAART duration in Denmark. 
The reference point for significance in this study was p < .05 and the decision to 
accept the null hypotheses for each sub-question were based on this reference point, 
while failure to reach statistical significance was set at the 95% confidence interval (CI). 
The 95% CI in all the models used implied that the odds in those with hypertension, 
obesity, and hyperglycemia fell within the ranges of the confidence interval 95% of the 
time.  
To minimize the possibility of a type II error, I interpreted the p-values taking into 
consideration the confidence intervals (CI). I also interpreted practical significance based 
on the effect sizes. It is noteworthy to say that the effect sizes obtained in this study were 
moderate to large. The medium to large effect size implied that the effect sizes are 
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sufficient to be of practical significance. The statistical and practical significance in the 
models supports the application of metabolic syndrome theory to the prevalence of 
hypertension, obesity, and hyperglycemia in this population. Lack of statistical 
significance in some cases may be that sample size was not big enough and did not 
necessarily mean that there was no association.  
Regarding practical significance of the findings, the effect of duration of HAART 
on obesity, hypertension, and hyperglycemia was moderate to large (effect size for 
obesity = 0.291, for hypertension = 0.380, and for hyperglycemia = 0.468). This result 
showed that duration of HAART supports the metabolic syndrome theory with the 
covariates adjusted. Thus, going by the metabolic syndrome theory, development of 
hypertension, obesity, and type 2 diabetes mellitus is an integrated and multi-staged 
process that involves several metabolic processes.  
Also, the inability to establish an association between HAART regimen and the 
metabolic syndrome components and failure to link NRTIs and NNRTI to the metabolic 
syndrome components could be due to the reason that only NRTIs and NNRTIs and no 
PIs drug combinations were used. This is supported by reports of other researchers that 
metabolic abnormalities are less likely to occur with NNRTI drug combinations (Hansen 
et al., 2009; Muhammed et al., 2013; Wu et al., 2012).  
Although causal relationships between HAART and hyperglycemia, obesity, and 
hyperglycemia could not be established in this study due to the nature of study design, 
information on the temporal associations upon which other studies can build was 
provided. This study also increases the body of knowledge. Results are pointers to the 
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fact that the length of time a patient is on HAART affect the metabolism of lipid and 
glucose, as well as the functions of adipose tissue. This effect on metabolism 
significantly influences metabolic syndrome in HIV patients on HAART regimen. Thus, 
in this study, HAART regimen for more than 12 months increased the odds of 
hypertension more than 9-fold; increased the odds of obesity more than 5-fold, and 
increased the odds of hyperglycemia more than 8-fold before adjustment. However, after 
adjusting for covariates, HAART regimen for more than 12 months increased the odds of 
hypertension more than 8-fold; decreased the odds of obesity one- fold, and increased the 
odds of hyperglycemia by more than six-fold.  
The confidence intervals obtained were fairly wide, but most of the results have 
intervals higher than 1.0. The high interval indicates the observed associations are truly 
significant, and, with a larger sample size, the interval would be narrowed.  
Association Between Immune Status and Metabolic Syndrome Components 
CD4+ cells are white blood cells that are vital and play significant role in the 
immune system (AIDS.gov, 2015). The CD4+ cell counts are used to monitor the 
immune status and disease progression in HIV patients. CD4+ cell count is a significant 
indicator of how well the immune system is (AIDS.gov, 2015). The normal CD4+ cell 
count for healthy adults and adolescents is between 500 cells/ml and 1,200 cells/ml. HIV-
infected individuals are usually initiated to commence HAART treatment when the count 
is < 350 cells/ml. There are conflicting reports on the association between CD4+ cell 
count and metabolic syndrome. While some previous studies found no association (Worm 
et al., 2009), other cross-sectional studies found that higher CD4 + cell count increased 
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the risk for metabolic syndrome (Alvarez, Salazar, & Galindez, 2010). Another cross-
sectional study found a different result of low CD4+cell count < 100 cells/ml to be 
associated with higher risk of metabolic syndrome (Bonfanti, De Socio, Marconi, et al., 
2010). This study however found statistically significant associations between CD4+ cell 
count and hypertension (χ2 = 45.140, p < .001), obesity (χ2 =14.117, p < .05), and 
hyperglycemia (χ2 = 25.702, p < .001). Their effect sizes were moderate to large. This 
result thus justified my inclusion of CD4+ as a covariate in the final model.  
In this study, being male, older age, and duration of HAART regimen were 
factors associated with developing hypertension, obesity, and hyperglycemia. Though not 
all the findings were statistically significant, this study is consistent with findings from 
previous similar studies. Comparing results of this study with results obtained in other 
populations regarding metabolic syndrome is a bit difficult. It is difficult because there 
are differences in methods, study designs, and data collection, as discussed in Chapter 2. 
There are no other similar studies that used secondary data, same methods, and design 
within this population with which to compare findings. Similar studies in other parts of 
Nigeria (northeast and the southwest) differed in study design and methods (Denue et al., 
2012; Muhammed et al., 2013). They used primary data for their studies so did Berhane's 
et al study in Ethiopia. 
In summary, this study is the first study to examine the relationship among 
HAART regimen and hypertension, obesity, and hyperglycemia; duration of HAART 
regimen and hypertension, obesity, and hyperglycemia in HIV patients in Umuahia 
metropolis. The odds of hypertension were more than 4-fold when on HAART for 12 
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months and more than 18-fold when on HAART for >12 months, compared to HIV 
patients on HAART for less than 12 months, after adjusting for covariates. Similarly, 
odds of obesity were nearly 2-fold when on HAART for 12 months and more than 5-fold 
when on HAART for >12 months. Similarly, odds of hyperglycemia were more than 3-
fold when on HAART for 12 months and more than 14-fold when on HAART for >12 
months. Statistical significance was achieved in the analyses of HAART duration on 
hypertension, obesity, and hyperglycemia after controlling for covariates. Regardless of 
the significant findings, this study has some limitations that are worthy of mention. I 
discuss these limitations in the following section.  
Limitations 
The first limitation of this study was the incomplete capture of patient’s data in 
the treatment care cards. Information such as family history of diabetes and hypertension 
were not recorded. Also not recorded was information on cigarette smoking, alcohol use, 
and socioeconomic status. These are possible confounders shown by other studies to be 
associated with metabolic syndrome (Alvarez, Salazar, Galindez et al., 2010). A second 
limitation was that the hemoglobin A1C (HbA1C) test which is a more reliable method of 
diagnosing diabetes was not recorded; similarly, there was no information on the use of 
anti-hypertensive and anti-diabetic medications.  
Since there were no sufficient indices for diabetes mellitus diagnosis, I decided to 
use only the fasting blood sugar (FBS) test report. Hence, I used the term hyperglycemia 
instead of diabetes mellitus where FBS was ≥100mg/dL. The third limitation was that 
there was no information on lipid profile in patients’ records. As a result, low-density 
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cholesterol and triglycerides assessment which are known risk factors from literature 
could not be assessed. The fourth limitation was that only NRTI and NNRTI-based 
regimens were used, and no PI-based regimens were used.  
Despite the strength of this study in the stratified method of sampling that should 
minimize bias and promote generalizability, the study results may not be generalizable 
beyond the study population because metabolic syndrome components differ by race, 
ethnicity, and region (Narayanan et al., 2010). Also, because of the limitations detailed 
above, the internal validity of my study results may be influenced. However, despite 
these limitations, some significant findings that are consistent with other cross-sectional 
and association studies were recorded. The validity of the metabolic syndrome 
components was supported by the ATP III criteria used to define hypertension and 
hyperglycemia and WHO criteria used to define obesity. Hypertension, obesity, and 
hyperglycemia were measured laboratory values that used gold standards and were 
recorded on the individual patients’ treatment care cards. The values were continuous and 
later dichotomized to reflect the presence or absence of each of the component.  
Conclusion 
The length of time an HIV-infected patient is on the HAART regimen 
significantly increased the odds of hypertension, obesity, and hyperglycemia. The odds 
are further increased when patients are older and are males. On the other hand, being on 
NNRTIs and NRTIs-based regimen alone did not increase the odds of hypertension, 
obesity, and hyperglycemia. In this study, prevalence of hypertension was higher than 
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prevalence rates recorded for obesity and hyperglycemia. Prevalence also increased with 
age, length of time on HAART, and higher in males.  
This study showed that while the immune statuses of patients were being 
improved through HAART regimen, patients were being predisposed to developing 
hypertension, obesity, and hyperglycemia. As a result, there is a need to assess HIV 
patients periodically for cardiovascular risk factors while on the regimen. Periodic 
assessment will ensure early detection and proper management of the risk factors and 
prevent the additional burden of heart disease. Thus, there is a need to create population 
awareness of the risks posed by being exposed to HAART regimen for a longer duration. 
There is also need to develop and implement lifestyle intervention programs for the HIV-
positive population undergoing anti-retroviral therapy in Umuahia metropolis. 
Recommendations 
Given the limitations of this study, and being the first study of this nature in 
Umuahia metropolis, a prospective study with primary data should be conducted to 
confirm these results. Data should include all the possible known confounders such as 
cigarette smoking, alcohol use, type of diet, physical activities, the use of anti-
hypertensive and anti-diabetic that were not recorded in patients’ medical records. 
Furthermore, because of the findings of this study that hypertension, obesity, and 
hyperglycemia increased with age, being male, and duration of treatment, I at this 
moment recommend that HIV patients on HAART regimen be monitored periodically for 
high blood pressure, obesity, and hyperglycemia. The periodic monitoring will make 
room for necessary control and management of the metabolic syndrome components, 
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especially in the older males. It is pertinent to note that metabolic syndrome components 
and the risk factors for metabolic syndrome are modifiable. As a result, lifestyle/behavior 
change intervention programs are advisable for HIV patients on HAART regimen. 
My findings provide population-based evidence that can be used by decision 
makers such as WHO, United States Agency for International Development (USAID), 
National Agency for the Control of AIDS (NACA), State Agency for the Control of 
AIDS (SACA), and the management of the Federal Medical Centre, Umuahia for policy 
making. Also, publishing findings will contribute to the wealth of scientific knowledge. 
There is the need for more studies to confirm the effects of specific risk factors and 
covariates such as length of time on HAART regimen, CD4+ cell count, age and sex that 
appeared to confer risk differently in HIV-infected patients. 
Implications 
In this study, the length of time a patient was placed on the HAART regimen 
played a significant contributory role in the prevalence of hypertension, obesity, and 
hyperglycemia. This has important implications for, metabolic syndrome theory, health 
care practice, and positive social change in this population. 
Implications for Metabolic Syndrome Theory 
Despite differences in study aims, design, and methods, results of this study are 
consistent with previous studies in similar populations, as well as other populations. The 
results also strengthened the general concept of the metabolic syndrome theory. Thus, 
metabolic syndrome components not only occur together, but their co-occurrence while 
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on HAART for more than 12 months was statistically significant as measured after 
adjusting for gender, age, and CD4+ cell count. 
Findings of this study showed that being on HAART regimen for more than 12 
months conferred the most risk for hypertension, obesity, and hyperglycemia; and the 
risks increased with older age, being male and lower CD4+ cell count. This expansion of 
the metabolic syndrome theory is supported by other studies (Alvarez, Salazar, Galindez 
et al., 2010; Bonfanti et al., 2010; Dimodi et al., 2014; Malangu, 2013). 
Implications for Health Care Practice 
In this study, the population-based evidence of risk factors that contribute to 
hypertension, obesity, and hyperglycemia were shown. These evidence-based risk factors 
can be taken into consideration by health care providers while caring for patients in this 
population. Findings in this study support the initiation of and periodic screening for 
hypertension, obesity, and hyperglycemia in HIV patients on HAART especially when 
they are older. The periodic screening will help to prevent occurrence of metabolic 
syndrome components. Also, efforts geared towards disease prevention should focus 
more attention on blood pressure, BMI, lipids, and fasting blood glucose measurements. 
This is because early detection and management can go a long way in preventing CVD, 
thereby preventing additional disease and financial burden on this population group.  
Though weight is routinely checked during clinic visits and height taken only at 
enrolment, the BMI was not calculated to screen for obesity. Thus, this should be 
addressed by health care providers. Also to be addressed by health care providers is the 
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inclusion of lipid profile tests as part of the routine tests conducted to enable assessment 
of the lipid profile of HIV patients while on HAART regimen.  
Implications for Positive Social Change 
Access to the findings of this study by HIV-infected patients through health talks 
or population-based intervention programs will equip them with knowledge of the risk 
factors for hypertension, obesity, and diabetes. By reducing the prevalence of metabolic 
syndrome components, the risk for CVD, diabetic complications such as blindness and 
amputation of the lower limbs, and kidney failure will be significantly reduced. 
Knowledge of study findings will also reduce or eliminate additional medical expenses 
caused by hospitalization as a result of chronic diseases, thereby improving the overall 
health and quality of life of this population. Furthermore, loss of income through reduced 
productivity as a result of ill health will also be minimized.  
 
119 
 
References 
Abebe, M., Kinde, S. Belay, G., Gebreegziabxier, A., Challa, F., Gebeyehu, T., & 
Tegbaru, B. (2014). Antiretroviral treatment associated hyperglycemia and 
dyslipidemia among HIV infected patients at Burayu health center, Addis Ababa, 
Ethiopia: A cross-sectional comparative study. BMC Research, 7, 380. 
doi:10.1186/1756-0500-7-380 
Adamson, C.S. (2012). Protease-mediated maturation of HIV: Inhibitors of protease and 
the maturation process. Molecular Biology International, 1,13. 
            doi:org/10.1155/2012/604261  
Agyemang-Yeboah, F., & Nkum, B. C. (2012). Scientific basis of healthcare. AIDS and 
pregnancy. In Victor R . Preedy (Ed), HIV/AIDS: An overview (pp. 1-16). Enfield, 
NH: Science Publishers.  
AIDS.gov. (2015). CD4 count. Retrieved from https://www.aids.gov/hiv-aids-basics/just-
diagnosed-with-hiv-aids/.../cd4-count/ 
Akinboro, A.O., Onayemi, O., Edward, A. O., Ayodele, M., D., Atiba, A. S. (2013).The 
impacts of first line highly active antiretroviral therapy on serum selenium, cd4 
count and body mass index: A cross sectional and short prospective study. Pan 
African Medical Journal, 15(97), 7─10. doi:10.11604/pamj.2013.15.97.2524  
Al Amoor, H. (2013). Quantitative methods: Sampling and data collection. Research for 
HealthProfessionals. Retrieved from https://www.linkedin.com/title/lecturer-at-
fatima-college-for-health-sciences.  
Alberti, K. G. M. M., & Zimmet, P. (2005). The metabolic syndrome- a new worldwide 
120 
 
definition. The Lancet, 366(9491), 1059–1062. 
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, 
K. A., & Smith, S. C. (2009). Harmonizing the metabolic syndrome: A joint 
interim statement of the International Diabetes Federation task force on 
epidemiology and prevention; National Heart, Lung, and Blood Institute; 
American Heart Association; World Heart Federation; International 
Atherosclerosis Society; and International Association for the study of obesity. 
Circulation, 120(16), 1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644 
Alencastro, P. R., Wolff, F. H., Oliveira, R. R., Ikeda, M. L.R., Barcellos, N. T., Brandão, 
A. B. M., & Fuchs, S. C. (2012). Metabolic syndrome and population attributable 
risk among HIV/AIDS patients: comparison between NCEP-ATPIII, IDF and 
AHA/NHLBI definitions. AIDS Research and Therapy, 9, 29. Retrieved from 
http://www.aidsrestherapy.com/content/9/1/29 
Alvarez, C., Salazar, R., & Galindez, J. (2010). Metabolic syndrome in HIV-infected 
patients receiving antiretroviral therapy in Latin America. Brazilian Journal of  
Infectious Diseases, 14(3), 256–263. 
American Diabetes Association. (n.d.). Living with diabetes: Heart disease. Retrieved 
from http://www.diabetes.org/living-with-diabetes/complications/heart-disease/. 
Anon. (1998). Body mass index: How to measure obesity. Clinical Guidelines on the  
identification, evaluation, and treatment of overweight and obesity in adults.  
The Evidence Report, 98(4083), 139–140.  
Arruda Junior, E. R., Lacerda, H. R., Moura, L. C. R., Albuquerque, M. F. P., & Filho, A. 
121 
 
(2010). Risk factors related to hypertension among patients in a cohort living with 
HIV/AIDS. Brazilian Journal of  Infectious Diseases,14(3), 281–287.  
Aschengrau, A., & Seage, G. R. (2008). Essentials of Epidemiology in Public Health (2nd 
ed.). Sudbury, MA: Jones & Bartlett.  
Bastard, J. P., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., Vidal, H. . . . Feve, B. 
(2006). Recent advances in the relationship between obesity, inflammation, and 
insulin resistance. European Cytokine Network, 17, 4–12. 
Banks, N. J. (1998). Designing medical record abstraction form. International Journal for 
Quality in Health Care, 10(2), 163–167. 
Beltrán-Sánchez, H., Harhay, M.O., Harhay, M.M., & McElligott, S. (2013). Prevalence 
and trends of metabolic syndrome in the adult U.S. population, 1999–2010. 
Journal of American College of Cardiology, 62(8), 697─703. doi: 
10.1016/j.jacc.2013.05.064  
Berhane, T., Yami, A., Alemseged, F., Yemane, T., Hamza, L., Kassim, M., & Deribe, K. 
(2012). Prevalence of lipodystrophy and metabolic syndrome among HIV positive 
individuals on Highly Active Anti-Retroviral treatment in Jimma, South West 
Ethiopia. The Pan African Medical Journal, 13, 43., Retrieved from 
http://www.panafrican-med-journal.com/content/article/13/43/full/ 
Biron, A., Bobin-Dubigeon, C., Volteau, C., Piroth, L., Perre, P., Leport, C., Prazuck, T., 
Jovelin, T., Billard, M., & Sebille, V. (2012). Metabolic syndrome in French 
HIV-infected patients: Prevalence and predictive factors after 3 years of 
antiretroviral therapy. AIDS Res Hum Retroviruses, 28(12), 1672–1678. doi: 
122 
 
10.1089/AID.2012.0048 
Bonfanti, P., De Socio, G.L., & Marconi, P. (2010). Is metabolic syndrome associated to 
HIV infection per se? Results from the HERMES study. Current HIV Resources, 
8(2), 165–171. 
Brown, T. T., Cole, S. R., Li, X., Kingsley, L. A., Palella, F. J., Riddler, S. A., Visscher, 
B. R. . . .Dobs, A. S. (2005). Antiretroviral therapy and the prevalence and 
incidence of diabetes mellitus in the multicenter AIDS cohort study. Archives of 
Internal Medicine, 165, 1179–1184. 
Brown, T. T., Xu, X., John, M., Singh, J., Kingsley, L.A., Palella, F. J. . . .Dobs, A. S. 
(2009). Fat distribution and longitudinal anthropometric changes in HIV-infected 
men with and without clinical evidence of lipodystrophy and HIV-uninfected 
controls: A sub study of the multicenter AIDS cohort study. AIDS research and 
therapy, 13, 6–8. doi:10.1186/1742-6405-6-8 
Burns, N., & Grove, S. K. (2005). The Practice of nursing research: Conduct, critique, 
and utilization (5th ed.). St. Louis, MO: Elsevier Saunders. 
Butt, A. A., McGinnis, K., Rodriguez-Barradas, M. C., Crystal, S., Simberkoff, M., 
Bidwell, M. . . .Justice, A. C. (2009). HIV infection and the risk of diabetes 
mellitus. AIDS, 23(10), 1227–1234. doi:10.1097/QAD.0b013e32832bd7af  
Centers for Disease Control and Prevention. (2013). Diabetes public health resource: 
Hospitalization. Retrieved from 
http://www.cdc.gov/diabetes/statistics/hospitalization_national.htm 
Centers for Disease Control and Prevention. (n.d.). Understanding the epidemiologic 
123 
 
triangle through infectious disease. Retrieved from 
http://www.bam.gov/teachers/activities/epi_1_triangle.pdf 
Chow, F. C., Regan, S., Feske, S., Meigs, J. B., Grinspoon, S. K., & Triant, V. A. (2012).  
Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected 
patients in a US health care system. Journal of Acquired Immune Deficiency 
Syndrome, 60(4), 351–358. 
Chukwuanukwu, R. C., Manafa, P.O., Ugwu, E. E., Onyenekwe, C. C., Oluboyo, A. O., 
Ezeugwunne, I. P., & Ogenyi, S. I. (2013). The incidence of diabetes mellitus 
among human immunodeficiency virus (HIV) positive patients on therapy in 
Nnewi. Journal of Nursing and Health Science, 2(3), 37–40. Retrieved from 
www.iosrjournals.org 
Cook, T. D., & Campbell, D. T. (1979). Quasi-experimentation: Design & analysis issues 
for field settings (English ed.). Boston, MA: Houghton Mifflin. 
Creswell, J. W. (2009). The Use of Theory, Research design: Qualitative, quantitative, 
and mixed methods approaches (3rd ed.). Thousand Oaks, CA: Sage. 
Crosby, R. A., Diclemente, R. J. & Salazar, L. F. (2006). Choosing a research design. In 
Author (Eds.). Research Methods in Health Promotion (pp. 75–106). San 
Fransisco, CA: Jossey-Bass.  
Currier, J. S. (2014). Cardiovascular disease associated with HIV infection. UpToDate. 
Retrieved from http://www.uptodate.com/contents/epidemiology-of-
cardiovascular-disease-and-risk-factors-in-hiv-infected-patients 
Denue, B. A., Muazu, P. J., Gashau, W., Mbo, D. N, & Ajayi, N. A. (2012). Effects of 
124 
 
highly active antiretroviral therapy (HAART) on blood pressure changes and its 
associated factors in HAART naive HIV-infected patients in northeastern Nigeria. 
Archives of Applied Science Research, 4 (3), 1447–1452. Retrieved from 
http://scholarsresearchlibrary.com/archive.html 
Department of Health and Human Services (2004). Guidelines for the use of 
antiretroviral agents in HIV-1-infected adults and adolescents. National Institutes 
for Health. Retrieved from aidsinfo.nih.gov/guidelines/adult/AA_111003.pdf 
Dimodi, H. T., Etame, L. S., Nguimkeng, B. S., Mbappe, F. E., Ndole, N. E., Tchinda, J 
. N. . . .Enyong, J. O. (2014). Prevalence of metabolic syndrome in HIV-infected 
Cameroonian patients. Journal of AIDS, 4, 85–92. Retrieved from 
http://www.scirp.org/journal/wja 
Diouf, A., Cournil, A., BaFall, K., Ngom-Gueye, N. F., Eymard-Duvernay, S.,  
Ndiaye, I. . . .Sow, P. S. (2012). Diabetes and hypertension among patients 
receiving antiretroviral treatment since 1998 in Senegal: Prevalence and 
associated factors,  AIDS. doi:10.5402/2012/621565 
Durand, M., Sheehy, O., Baril, J. G, Lelorier, J., & Tremblay, C. L. (2011). Association 
between HIV infection, antiretroviral therapy, and risk of acute myocardial 
infarction: a cohort and nested case-control study using Québec's public health 
insurance database. Journal of Acquired Immune Deficiency Syndrome, 57(3), 
245-253. 
Engel, L., Henderson, C., Fergenbaum, J., & Colantonio, A. (2009). Medical record 
review conduction model for improving inter-rater reliability of abstracting 
125 
 
medical-related information. Evaluation Health Professionals, 32(3), 281-298. 
Ervin, R. B. (2009). Prevalence of metabolic syndrome among adults 20 years of age and 
over, by sex, age, race and ethnicity, and body mass index: United States, 2003-
2006. National Health Statistics Reports, 13. Retrieved from 
http://www.cdc.gov/nchs/data/nhsr/nhsr013.pdf 
Explorable.com. (n.d.). Stratified sampling method. Retrieved from 
https://explorable.com/stratified-Sampling. 
Faul, F., Erdfelder, E., Buchner, A., & Lang, A. G. (2009). Statistical power analyses 
using G*Power 3.1: Tests for correlation and regression analyses. Behavior 
Research Methods, 41, 1149–1160. 
Federal Medical Centre Umuahia. (2014). ART overview. Retrieved from 
http://www.fmcumuahia.com/ART.html 
Feleke, Y., Fekade, D & Mezegebu, Y. (2012). Prevalence of highly active antiretroviral 
therapy associated metabolic abnormalities and lipodystrophy in HIV infected 
patients. Ethiopian Medical Journal, 50(3), 221–230.  
Ferng, S. (n.d.). Investigational tools: Epidemiology, microbiology, and toxicology. 
Retrieved from http://www.cdc.gov/nceh/ehs/nalboh/nalboh-5.pdf  
Ferrannini, E. (2007). Metabolic syndrome: a solution in search of a problem. Journal of 
Clinical Endocrinology Metabolism, 92, 396–398.  
Field, A. (2009). Assumptions and things that can go wrong. Discovering statistics using 
SPSS (3rd ed). 265-315. Thousand Oaks, CA: SAGE. 
Fontas, E., van Leth, F., Sabin, C.A., Friis-Moller, N., Rickenbach, M., D. Arminio, M. 
126 
 
A. . . .Mateu, S. (2004). Lipid profiles in HIV-infected patients receiving 
combination antiretroviral therapy: Are different antiretroviral drugs associated 
with different lipid profiles? Journal of Infectious Diseases, 189, 1056-1074. 
Francisci, D., Giannini, S. & Baldelli, F. (2009). HIV type 1infection, and not short-term 
HAART, induces endothelial dysfunction,  AIDS, 23(5), 589–596. 
Frankfort-Nachmias, C., & Nachmias, D. (2008). Research methods in the social sciences 
(7th ed.). New York, NY: Worth.  
Freiberg, M. S, Chang, C. C., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L. . . 
.Justice, A. C. (2013). HIV infection and the risk of acute myocardial infarction. 
JAMA of International Medicine, 173(8), 614. 
Friis-Moller, N., Sabin, C. A., & Weber, R. (2003). Combination antiretroviral therapy 
and the risk of myocardial infarction, The New England Journal of Medicine, 
349(21), 1993–2003. 
Gaziano, T.A., Bitton, A., Anand, S., Abrahams-Gessel, S., & Murphy, A. (2010). 
Growing epidemic of coronary heart disease in low- and middle-income 
countries. Current Problems in Cardiology, 35, 72–115.  
Gazzaruso, C., Bruno, R., Garzaniti, A., Giordanetti, S., Fratino, P., & Sacchi, P. (2003). 
Hypertension among HIV patients: Prevalence and relationships to insulin 
resistance and metabolic syndrome. Journal of Hypertension, 21, 1377–1382. 
Gersh, B. J., Sliwa, K., Mayosi, B. M., & Yusuf, S. (2010). Novel therapeutic concepts: 
the epidemic of cardiovascular disease in the developing world: Global 
implications. European Heart Journal, 31, 642–648. 
127 
 
Glucose. (2015). In Merriam-Webster’s online dictionary. Retrieved from 
http://www.merriam-webster.com/dictionary/glucose 
Grinspoon, S. (2003). Mechanisms and strategies for insulin resistance in Acquired 
Immune Deficiency Syndrome. Clinical Infectious Diseases, 37(2), 85-90. 
Grinspoon, S. (2009). Diabetes Mellitus, Cardiovascular risk, and HIV disease. 
Circulation, 119, 770-772. Retrieved from http://circ.ahajournals.org 
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004). 
Definition of metabolic syndrome report of the national heart, lung, and blood 
institute/American heart association conference on scientific issues related to 
definition. Circulation, 109, 433-438. Retrieved from 
http://circ.ahajournals.org/content/109/3/433 
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A. 
. . .Costa, F. (2005). American heart association; national heart, lung, and blood 
institute: Diagnosis and management of the metabolic syndrome: an American 
heart association/national heart, lung, and blood institute scientific tatement. 
Circulation, 112, 2735–2752.  
Grundy, S. M. (2006). Metabolic syndrome: Connecting and reconciling cardiovascular 
and diabetes worlds. Journal of the American College of Cardiology, 47(6), 1093- 
1100. doi:10.1016/j.jacc.2005.11.046 
 Guaraldi, G., Stentarelli, C., Zona, S., Orlando, G., Carli, F., Ligabue, G. . . . Raggi, P. 
(2010). Lipodystrophy and antiretroviral therapy as predictors of sub-clinical 
atherosclerosis in human immunodeficiency virus infected subjects.  
128 
 
Atherosclerosis, 208(1), 222–227. 
Hall, P., Schroder, C., & Weaver, L. (2002). The last 48 hours of life in long-term care: A  
focused chart audit. Journal of American Geriatric Society, 50(3), 501-506. 
Hansen, B.R., Petersen, J., Haugaard, S.B., Madsbad, S., Obel, N., Suzuki, Y., & 
Andersen, O. (2009). The prevalence of metabolic syndrome in Danish patients 
with HIV infection: The effect of antiretroviral therapy. HIV Medicine, 10(6), 
378–387. doi:10.1111/j.1468-1293.2009.00697.x 
Haugaard, S. B., Andersen, O., & Storgaard, H. (2004). Insulin secretion in 
lipodystrophic HIV-infected patients is associated with high levels of no glucose 
secretagogues and insulin resistance of β-cells. American Journal of Physiology, 
287(4), 677–685. 
Hess, D.R. (2004). Retrospective studies and chart review. Respiratory Care, 49(10), 
1171-1174.  
Howard, B. V., Rodriguez, B. L., Bennett, P. H., Harris, M. L., Hamman, R., Kuller, 
L.H., & Wylie-Rosett, J. (2002). Prevention conference VI: Diabetes and 
cardiovascular disease writing group I: Epidemiology. Circulation, 105, 132. –
137.  
Hsue, P. Y., Hunt, P. W., & Schnell, A. (2009). Role of viral replication, antiretroviral 
therapy, and immunodeficiency in HIV-associated atherosclerosis, AIDS, 23(9), 
1059–1067.  
Hsue, P. Y., Hunt, P.W., & Wu, Y. (2009). Association of abacavir and impaired 
endothelial function in treated and suppressed HIV-infected patients, AIDS, 
129 
 
23(15), 2021–2027. 
International Diabetes Federation. (2006). The IDF consensus worldwide definition of the 
metabolic syndrome. Brussels, Belgium: IDF communications. Retrieved from 
http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf 
International Diabetes Federation. (2011). IDF diabetes atlas: Global estimates of the 
prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical 
Practice, 3(94), 311–321. doi.org/10.1016/j.diabres.2011.10.029 
Institute of Medicine. (2003a). The future of the public’s health in the 21st century. The 
National Academy of Press, Washington, DC.  
Institute of Medicine. (2003b). Who Will Keep the Public Healthy? Educating Public 
Health Professionals for the 21st Century. Washington, DC: The National 
Academies Press.  
Jacobson, D. L., Tang , A. M., Spiegelman, D., Thomas, A. M., Skinner, S., & Gorbach, 
S.L. (2006). Incidence of metabolic syndrome in a cohort of HIV-infected adults 
and prevalence relative to the US population: National health and nutrition 
examination survey. Journal of Acquired Immune Deficiency Syndrome, 43, 458–
4566. 
Jones, R., Sawleshwarkar, S., Michailidis, C., Jackson, A., Mandalia, S., Stebbing, J. . . 
.Moyle, G. J. (2005). Impact of antiretroviral choice on hypercholesterolaemia 
events: The role of the nucleoside reverse transcriptase inhibitor backbone. HIV 
Medicine, 6, 396-402. 
Kamangar, F. (2012). Confounding variables in epidemiologic studies: Basics and 
130 
 
beyond. Archaeology of Iranian Medicine, 15(8), 508–516. 
Kaneko, M. Suzuki, H., Watanabe, H., Oda, E., & Aizawa, Y. (2011). Metabolic 
syndrome is a poor predictor of incident diabetes compared with hemoglobin A1c 
(Hba1c) in a general Japanese population. Journal of Diabetes and Metabolism, 2, 
001. doi:10.4172/2155-6156.S2-001 
Kannel, W. B., & McGee, D. L. (1979). Diabetes and glucose tolerance as risk factors for 
cardiovascular disease: The framingham study. Diabetes Care, 2(2), 120-126. 
Kaplan, N. M. (1989). The deadly quartet: Upper-body obesity, glucose intolerance, 
hypertriglyceridemia, and hypertension. Archives of Internal Medicine, 149, 
1514-1520. 
Karabi,N. (2012). Understanding and quantifying effect sizes. Retrieved from  
nursing.ucla.edu/workfiles/research/Effect%20Size%204-9-2012.pdfKelley  
Katz, M. H., (2006). Multivariable analysis. A practical guide for clinicians. Cambridge, 
UK: University Press.  
 
Kelley, K., & Preacher, K. J. (2012). On effect size. Psychological Methods, 17(2), 137–
152. doi:10.1037/a0028086 
Kiage, J. N., Heimburger, D. C., Nyirenda, C. K., Wellons, M. F., Shashwatee, B. S., Chi, 
B. H. . . .Kabagambe, E. K. (2013). Cardiometabolic risk factors among HIV 
patients on antiretroviral therapy. Lipids in Health and Disease, 12, 50. 
doi:10.1186/1476-511X-12-50 
Kingsley, L. A., Cuervo-Rojasc, J., Muñozc, A., Palellad, F. J., Poste, W., Wittf, M. D. . . 
131 
 
.Kuller, L. (2008). Subclinical coronary atherosclerosis, HIV infection and 
antiretroviral therapy: Multicenter AIDS cohort study. AIDS, 22(13), 1589–1599.  
Kolpepaj, R., Shkurti, E., Nake, A., Harxhi, A., Kolici, E., & Capi, K. (2015). 
Association of highly active antiretroviral treatment for HIV disease and 
metabolic issues. Academic Journal of Interdisciplinary Studies, 4(1), 153– 
160. Rome-Italy: MCSER. 
Kumarasamy, N., VenKatesh, K. K., Cecelia, A. J., DeValeenal, B., Lai, A. R., & Mayer, 
K. H. (2008). Spectrum of adverse events after generic HAART in southern 
Indian HIV-infected patients. AIDS Patient Care and STDs, 22(4), 337–44. 
doi:10.1089/apc.2007.0093 
Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A. . . 
.Costagliola, D. (2010). Increased risk of myocardial infarction in HIV-infected 
patients in France, relative to the general population. AIDS, 24(8), 1228–1230. 
 Lauda, L. G., Mariath, A. B., & Grillo, L. P. (2011). Metabolic syndrome and its 
components in HIV-infected individuals. Review of Association of Medicines, 57, 
2. doi.org/10.1590/S0104-42302011000200016  
Lee, G. A., Rao, M. N. & Grunfeld. C. (2005). The effects of HIV protease inhibitors on 
carbohydrate and lipid metabolism. Current HIV/AIDS Report, 2(1), 39–50.  
Liang, J. S., Distler, O., & Cooper, D. A. (2001). HIV protease inhibitors protect Apo 
lipoprotein B from degradation by the proteasome: a potential mechanism for 
protease inhibitor induced hyperlipidemia. Nature Medicine, 7(12), 1327–1331. 
Liehr, P. & Smith, M. J. (1999). Middle range theory: Spinning research and practice to 
132 
 
create knowledge for the new millennium. Advances in Nursing Science, 21(4), 8–
91. 
Malangu, N. (2014).Factors associated with metabolic syndrome among HIV-positive 
patients at a health facility in Botswana. British Journal of Medicine & Medical 
Research, 4(12), 2352–2361. 
May, M. T, Sterne, J. A, Costagliola, D. (2006). HIV treatment response and prognosis in 
Europe and North America in the first decade of highly active antiretroviral 
therapy: A collaborative analysis. Lancet, 368:451. 
McKenna, M., & Collins, J. (2010). Current issues and challenges in chronic disease 
control. In P. L. Remington, R. C. Brownson, & M. V. Wegner (Eds.), Chronic 
disease epidemiology and control (3rd ed, pp. 1–26).Washington, DC: American.  
Meier, K. J., Brudney, J. L., & Bohte, J. (2011). Applied Statistics for Public and Non-
profit Administration (8th ed.). Boston, MA: Wadsworth Cengage. 
Mente, A. Yusuf, S., Islam, S., McQueen, M. J., Tanomsup, S., Onen, C. L. . . .Anand, S. 
S. (2010). Metabolic syndrome and risk of acute myocardial infarction: A case-
control study of 26,903 subjects from 52 countries. JACC, 55(21), 2390–2398. 
Mhlabi, D.B. (2011). Metabolic syndrome among people with human immunodeficiency 
virus on anti-retroviral therapy at Princess Marina Hospital in Gaborone-
Botswana. Student thesis. Retrieved from http://ul.netd.ac.za/handle/10386/411 
Mills, E., Cooper, C., Seely, D., & Kanfe, I. (2005). African herbal medicines in the 
treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and 
pharmacology. Nutrition Journal, 4, 19. doi:10.1186/1475-2891-4-19 
133 
 
Mohan, V. & Deepa, M. (2006). The metabolic syndrome in developing countries. 
Diabetes Voice, 51. Retrieved from 
https://www.idf.org/sites/default/files/attachments/article_410_en.pdf 
Mozumdar, A., & Liguori, G. (2011). Persistent increase of prevalence of metabolic 
syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes 
Care, 34, 216–219.  
Muhammad, S. Sani, M. U., & Okeahialam, B.N. (2013). Cardiovascular disease risk 
factors among HIV-infected Nigerians receiving highly active antiretroviral 
therapy. Nigerian Medical Journal, 54(3), 185–190. doi:10.4103/0300-
1652.114591 
Narayan, K. M. V., Ali, M. K., & Koplan, J. P., (2010). Global noncommunicable 
diseases - where worlds meet. New English Journal of Medicine, 363, 1196–
1198.doi:10.1056/NEJMp1002024 
National Cholesterol Education Program. (2002). Third report of the National 
CholesterolEducation Program (NCEP) expert panel on detection, evaluation, 
and treatment of highblood cholesterol in adults (ATP III), executive summary. 
Washington, DC: National 
National Heart, Lung, and Blood Institute, National Institutes of Health. (2011). What is 
cholesterol? Retrieved from 
http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf 
National Heart, Lung and Blood Institute. (2011). what is high blood pressure? Retrieved 
from http://www.nhlbi.nih.gov/health/health-topics/topics/hbp/. 
134 
 
Nicholols, G. A. & Moler, E. J. (2010). Diabetes incidence for all possible combinations 
of metabolic syndrome components. Diabetes Research and Clinical Practice, 90,  
115-121. doi:10.1016/j.diabres.2010.06.011 
Ngatchoua, W., Lemogouma, D., Ndobob, P., Yiagnignib, E., Tiogoub, E., Ngab, E. . . 
.Leemana, M. (2013). Effects of antiretroviral therapy on arterial stiffness in 
Cameroonian HIV-infected patients. Blood Pressure Monitoring, 18(5), 247-251. 
Nwadinma, O. (2013, November 8). Health minister’s impression of Umuahia FMC feat. 
The Sun. Retrieved from http://sunnewsonline.com/new/health-ministers- 
impression-umuahia-fmc-feat/ 
Okafor, C. I. (2012). The metabolic syndrome in Africa. National center for 
biotechnology information. U.S. national library of medicine. Current Trends, 16. 
Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263198/ 
Omech, B., Sempa, J., Castelnuovo, B., Opio, K., Otim, M., Mayanja-Kizza. . . .Manabe, 
Y. C. (2012). Prevalence of HIV associated metabolic abnormalities among 
patients taking first-line antiretroviral therapy in Uganda. International Scholarly 
Research Network AIDS, 6. doi:10.5402/2012/960178 
Palacios, R., Santos, J., García, A., Castells, E., González, M., Ruiz, J. & Márquez. M. 
(2006). Impact of HAART on blood pressure in HIV-infected patients. A 
prospective study in a cohort of naive patients HIV. Medicine, 7(1), 10–
15. Retrieved from http://www.medscape.com/viewarticle/518813_print 
Palios, J. Kadoglou, N.P. E., & Lampropoulos, S. (2012). The pathophysiology of HIV-
/HAART-related metabolic syndrome leading to cardiovascular disorders: The 
135 
 
emerging role of adipokines. Experimental Diabetes Research, 1–7. 
doi:10.1155/2012/103063 
Panacek, E.A. (2007). Basics of research part 8: Performing chart review studies. Air 
Medical Journal, 26(5), 206-210. 
Paula, A. A., Falcão, M. C.N., & Pacheco, A.G. (2013). Metabolic syndrome in HIV-
infected individuals: underlying mechanisms and epidemiological aspects. AIDS 
Research and Therapy, 10:32. Retrieved from 
http://www.aidsrestherapy.com/content/pdf/1742-6405-10-32.pdf 
Passalaris, J. D., Sepkowitz, K. A., & Glesby, M. J. (2000). Coronary artery disease and 
human immunodeficiency virus infection. Clinical Infectious Disease, 31, 787-
797 
Post, W. S., Budoff, M., Kingsley, L., Palella, F. J., Witt, M. D., Li, X. . . .Jacobson, L. P. 
(2014). Associations between HIV infection and subclinical coronary 
atherosclerosis: The multicentre AIDS cohort study (MACS). Ann Intern Med, 
160(7), 458-467. 
Ranganathan, S. & Kern, P. A. (2002). The HIV protease inhibitor saquinavir impairs 
lipid metabolism and glucose transport in cultured adipocytes, Journal of 
Endocrinology, 172(1), 155–162. 
Razzouk, L.& Muntner, P. (2009). Ethnic, gender, and age-related differences in patients 
with the metabolic syndrome. Current Hypertension Report, 11(2), 127–32. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19278602  
Reaven, G.M.. (1988). Banting lecture 1988: Role of insulin resistance in human disease. 
136 
 
Diabetes, 37, 1595–1607. 
Reaven, G. M. (2011). The metabolic syndrome: Time to get off the merry-go-round? 
Journal of Internal Medicine, 269, 127-136. doi:10.1111/j.1365-
2796.2010.02325.x 
Roger, V.L. (2011). Heart disease and stroke statistics--2011 update: a report from the 
American heart association. Circulation, 123, 18–209. 
Rosolova, H., & Nussbaumerova, B. (2011). Cardio-metabolic risk prediction should be 
superior to cardiovascular risk assessment in primary prevention of cardiovascular 
diseases. EPMA J, 2, 15–26.  
Sachithananthan, V., Loha. E., & Gose, M. (2012). Prevalence of diabetes mellitus,  
hypertension and lipodystrophy in HAART receiving HIV patients in southern 
Ethiopia. International STD Research & Reviews, 1(1), 1-11. 
Schneider, C. (2014). Metabolic syndrome and diabetes. DiabetesCare.net, 11(3), 271–
278. Retrieved from http://www.diabetescare.net/authors/clara-
schneider/metabolic-syndrome-diabetes 
Schulman, I. H., & Zhou, M. S. (2009). Vascular insulin resistance: a potential link 
between cardiovascular and metabolic diseases. Current Hypertension, 11, 48–55.  
Sharma, A., Bynum, S. A., Schneider, M. F., Cox, C., Tien, P. C., Hershow, R. C. . . 
.Plankey, M. W. (2014). Changes in body mass index following HAART 
initiation among HIV infected women in the women’s interagency HIV study. 
Journal of AIDS Clinical Resources, 5, 7. doi.org/10.4172/2155-6113.1000323  
Stein, J. H., & Hsue, P.Y. (2012). Inflammation, immune activation, and CVD risk in 
137 
 
individuals with HIV infection. JAMA, 308, 405. 
Steinhart, C. R., & Emons, M. F. (2004). Risks of cardiovascular disease in patients 
receiving antiretroviral therapy for HIV infection: implications for treatment. 
AIDS Read, 14(2), 86-90. 
Stem, M.P. (1997). The insulin resistance syndrome. International Textbook of Diabetes 
Mellitus (2nd ed.). Charlseton, WV: John Wiley. 
StraightHealthcare. (2015). Covariates and Confounders. Retrieved from 
http://www.straighthealthcare.com/confounder-covariate.html 
Subbaraman, R., Chaguturu, S. K., Mayer, K. H., Flanigan, T. P. & Kumarasamy, N. 
(2007). Adverse effects of highly active antiretroviral therapy in developing 
countries. Clinical Infectious Diseases, 45, 1093-1101. 
Szklo, M., & Nieto, F. J. (2014). Epidemiology: beyond the basics. (3rd ed.). Burlington, 
MA: Jones & Bartlett. 
Tadewos, A., Addis, Z., Ambachew, H., & Banerjee, S. (2012). Prevalence of 
dyslipidemia among HIV-infected patients using first-line highly active 
antiretroviral therapy in Southern Ethiopia: A cross-sectional comparative group 
study. AIDS Research and Therapy, 9, 31. Retrieved from 
http://www.aidsrestherapy.com/content/9/1/31 
The GPS Coordinates.net. (n.d.). The latitude and longitude gps coordinates of Umuahia  
(Nigeria). Retrieved from http://thegpscoordinates.net/nigeria/umuahia 
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007). Increased acute 
myocardial infarction rates and cardiovascular risk factors among patients with 
138 
 
human immunodeficiency virus disease. Journal of Clinical Endocrinology 
Metabolism, 92, 2506–2512.  
University of Toronto. (n.d.). Final Report: Rehabilitation services for people living with 
HIV/AIDS: Development of a national survey of health care provider groups. 
Retrieved from 
www.hivandrehab.ca/EN/.../University_Toronto_survey_project.pdf 
Villamar, Albuja, & Salas. (2011). Metabolic syndrome among HIV-infected outpatients 
from a  hospital in Quito, Ecuador: a cross-sectional study. Review of Pan-
American Infectology, 13(2), 12-18. 
Wang, C. C. L., Goalstone, M. L., & Draznin, B. (2004). Perspectives in diabetes: 
Molecular mechanisms of insulin resistance that impact cardiovascular biology. 
Diabetes, 53(11), 2735-2740. 
Wang, K., Li, M. & Hakonarson, H. (2010). Analyzing biological pathways in genome-
wide  association studies. Nature Reviews Genetics, 11, 843-854. 
doi:10.1038/nrg2884 
Wannamethee, S.G. (2008). The metabolic syndrome and cardiovascular risk in the 
British regional heart study. International Journal of Obesity, 32(2), 25–29. 
Wickson-Griffiths, A., Kaasalainen, S., Ploeg, J. & McAiney, C. (2014). Revisiting 
retrospective   chart review: An evaluation of nursing home palliative and end-of-
life care research. Palliative medicine and care. Retrieved from 
http://www.symbiosisonline.org 
Wilcox, G. (2005). Insulin and insulin resistance. Clinical Biochemistry Reviews, 26(2), 
139 
 
19-39. 
Wilson, R. (2015). Binary interaction parameter. Retrieved from 
http://cheguide.com/tag/binary-interaction-parameter/ 
World Health Organization. (1999). Definition, diagnosis and classification of diabetes 
mellitus and its complications: report of a WHO Consultation. Part 1: Diagnosis 
and classification of diabetes mellitus. 
http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf  
World Health Organization. (2014). Antiretroviral therapy. Retrieved from 
http://www.who.int/topics/antiretroviral_therapy/en/ 
World Health Organization. (2015). Obesity and overweight. Retrieved from 
http://www.who.int/mediacentre/factsheets/fs311/en/ 
World Medical Association. (2008). Declaration of Helsinki. World Medical Journal, 
54(4), 120-25. Retrieved from 
https://en.wikipedia.org/wiki/Declaration_of_Helsinki 
Worm, S. W., Friis-Moller, N., Bruyand, M., Monforte, A. D., Rickenbach, M., Reiss, P. 
. . .Sabin, C. (2010). High prevalence of the metabolic syndrome in HIV-infected 
patients: Impact of different definitions of the metabolic syndrome. AIDS, 24(3), 
427–435. 
Wu, P., Hung, C., Liu, W., Hsieh, C., Sun, H., Lu, C. . . .Chien, K. (2012). Metabolic 
syndrome among HIV-infected Taiwanese patients in the era of highly active 
antiretroviral therapy: Prevalence and associated factors. Journal of Antimicrobial 
Chemotherapy, 67, 1001–1009. doi:10.1093/jac/dkr558 
140 
 
Zha, B. S., Studer, E. J., Zha, W., Hylemon, P. B., Pandak, W., & Zhou, H. 
(2011.).Highly active antiretroviral therapy (HAART) and metabolic 
complications. In Prof. Yi-Wei Tang (Ed). Recent Translational Research 
HIV/AIDS (pp. 253–274). Rijeka, Croatia: InTech.  
Zhou, M. S., Schulman, I. H., & Zeng, Q. (2012). Link between the renin-angiotensin 
system and insulin resistance: Implications for cardiovascular disease. Vascular 
Medicine, 17, 330–341. doi:10.1177/1358863X12450094 
Zhou, M. S., Wang, A., & Yu, H. (2014). Link between insulin resistance and 
hypertension: What is the evidence from evolutionary biology? Diabetology & 
Metabolic Syndrome, 6, 12. Retrieved from 
http://www.dmsjournal.com/content/6/1/12. 
Zimmet, P. Z. (1992). Kelly West lecture 1991. Challenges in diabetes epidemiology-
from west to rest. Diabetes Care, 15(2), 232-252. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/1547680 
141 
 
Appendix A: Data Abstraction Form  
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